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ABSTRACT 
Near-Infrared Silica-Based Gold Nanoshells as Potential Rapid Diagnostic Imaging 
Agents for Breast Cancer Tumor Detection 
by 
Lissett Ramirez Bickford 
Although much research has focused on using near-infrared silica-based gold 
nanoshells for dual-imaging and therapeutic applications in vivo, these particles may also 
prove useful as rapid diagnostic imaging agents for ex vivo applications, such as 
intraoperative tumor margin detection. In this thesis, gold nanoshells were successfully 
designed to target breast cancer cells through antibodies against the extracellular Human 
Epidermal growth factor Receptor 2 (HER2) , whose overexpression is associated with 
more aggressive forms of breast cancer. By comparing HER2-positive breast cancer cells 
to normal (nonneoplastic) breast cells, the nanoshells effectively labeled HER2-
overexpression within 5 minutes of incubation time. These nanoshells also enhanced 
contrast of the same cancer cells using two-photon microscopy, which enabled 
subsequent validation of preferential labeling using a distinctive co-culture experiment. 
To ultimately translate these findings to the clinic, nanoshells of similar design 
were studied for their effectiveness at enhancing contrast of malignancy in breast tissue 
sections and intact human breast tissue. Through detailed experimental conditions, these 
nanoshells increased contrast of cancer cells in sectioned HER2-overexpressing breast 
tissue within 5 minutes of incubation time using reflectance confocal microscopy, a 
unique imaging capability not previously reported. Finally, these targeted nanoshells 
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were used to effectively visualize HER2 receptor expression in intact human breast tissue 
specimens within the same 5 minute incubation time point. Through two-photon imaging, 
it was shown that these nanoparticies preferentially labeled tissue surface receptors, with 
minimal penetration depth. Importantly, the enhanced surface labeling was observed 
macroscopically through a standard stereomicroscope and confirmed microscopically 
through reflectance confocal microscopy and immunohistochemistry. These results 
suggest that anti-HER2-nanoshells used in tandem with a near-infrared reflectance 
confocal microscope and a standard stereomicroscope may potentially be used to discern 
HER2-overexpressing cancerous tissue from normal tissue in near real time and offer a 
rapid supplement to current diagnostic techniques. 
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CHAPTER! 
THESIS OVERVIEW 
Due to their advantageous and flexible optical properties, silica-based gold 
nanoshells, which have a dielectric silica core and a gold outer shell, were studied for 
their imaging potential as rapid contrast agents for the HER2/neu biomarker. This 
assessment began with a look at their rapid labeling ability in in vitro cell studies, 
followed by ex vivo tissue sections and, lastly, intact (non-sectioned) tissue specimens. 
Crucial to confirming experimental results and understanding mechanisms of nanoshell-
targeting, the effectiveness of using gold nanoshells as contrast agents for two-photon 
microscopy was also analyzed and the utility of this more recent discovery was 
demonstrated through in vitro cell studies and ex vivo tissue studies. 
Beginning in Chapter 2, the potential use of silica-based gold nanoshells as rapid 
imaging agents for breast cancer tumor margin detection is considered. Although it is 
expected that the ability to use these nanoparticles for near-real time diagnostics will 
unlock many possibilities, their potential for assisting surgeons in delineating tumor 
margins intraoperatively is more closely evaluated. Currently, tumor margins are 
determined outside of the operating suite and several days or weeks may elapse before a 
result is presented to the patient. By employing gold nanoshells as rapid diagnostic 
imaging agents, surgeons and pathologists may be able to arrive at conclusive 
information without further delay or the need for repeat procedures. 
Next, in Chapter 3, current methods employed for tumor margin detection are 
explained. 1 These methods include those in practice at both tertiary care centers and at 
1 
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ue to their advantageous and flexible optical properties, silica-based gold 
nanoshells, which have a dielectric silica core and a gold outer shell, were studied for 
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overexpression, is desired. Chapter 6 begins by examining the ability of anti-HER2-
targeted nanoshells to preferentially label HER2 receptors in an in vitro cell study using a 
time-based analysis.21 Although former studies have shown successful targeting of 
HER2-overexpressing cell lines using HER2-targeted nanoshells3,5, this chapter describes 
larger, more scattering-based nanoshells designed to enhance HER2-overexpression 
within only 5 minutes of incubation time. Furthermore, the approximate number of 
nanoshells bound per cell at both 5 and 60 minutes is determined and it is shown that an 
estimated 95% of the nanoshells in solution bind within the first 5 minutes of incubation 
time. This work, which demonstrated the proof of concept that nanoshells may offer 
rapid labeling opportunities in vitro, was subsequently published in 2008 in 
NanoBiotechnology. 
While gold nanoshells have commonly been shown to serve as diagnostic imaging 
agents for darkfield microscopy3,5,21, their use as contrast agents under two-photon 
microscopy has not been as thoroughly studied. In Chapter 7, the two-photon 
characteristics of two different-sized silica-gold nanoshells are first validated and their 
wide-spanning emission range under two-photon excitation is shown?2 Owing to this 
wide-spanning emission range, the ability to specifically label HER2-overexpressing cells 
after only 5 minutes is confirmed through a unique co-culture experiment employing two-
photon microscopy. In Chapter 9, this relatively new application is revisited when two-
photon microscopy is utilized again for the visualization of nanoshells on the surface of 
intact ex vivo breast tissue specimens. This research, which showed the utility of gold 
nanoshells for two-photon unagmg of breast cancer cells, . was published in 
Nanotechnology in 2008. 
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F onnerly, through in vitro cell studies, targeted nanoshells were shown as rapid 
diagnostic imaging agents for HER2-overexpression. However, in order for this new 
potential application to make its way to the clinical realm, it is imperative that more 
clinically-geared experiments ensue. Thus, in Chapter 8, this work is advanced to include 
sectioned breast tissue specimens.23 Moreover, while previous studies considered 
nanoshell-enhanced contrast of cells observed through a darkfield microscope, 
nanoshells' potential as contrast agents for reflectance confocal microscopy, an imaging 
modality capable of looking at thicker tissue specimens, is revealed. First, nanoshells 
demonstrated enhanced contrast of HER2-overexpressing cells using reflectance confocal 
microscopy. Next, a procedure is described for visualizing HER2-overexpression in 
sectioned breast tissue within only 5 minutes of incubation time with a reflectance 
confocal microscope. Importantly, labeling results with HER2-targeted nanoshells was 
supported by immunohistochemistry experiments against the HER2 biomarker.23 This 
research was consequently published in the journal Breast Cancer Research and 
Treatment in 2010. 
While the evaluation of tissue sections is the current method of microscopic 
disease verification (as will be described in Chapter 3i4, the ability to realize the extent 
of disease macroscopically is highly desirable. By doing so, the regions of interest that 
remain questionable could be minimized without the need for further tissue sectioning 
and processing. In light of this, Chapter 9 describes the use of silica-gold nanoshells as 
rapid imaging agents for the widefield imaging of intact human breast tissue specimens 
through the use of a standard stereomicroscope. Two-photon microscopy is first 
employed to assess the possible depth of penetration of the nanoshells after 5 minutes of 
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incubation time. As expected, these nanoshells preferentially targeted and labeled HER2 
receptors on the surface of HER2-overexpressing tissue. Furthermore, through the use of 
a standard stereomicroscope, the rapid labeling of HER2-overexpressing tissue is shown 
without image manipulation and these results are validated by both reflectance confocal 
microscopy and immunohistochemistry against HER2. Currently, this work is in 
preparation for submission to Breast Cancer Research and Treatment. 
In conclusion, in Chapter 10, a summary of research findings is presented in 
addition to the future direction of translating this work into a usable clinical supplement 
to current diagnostic techniques, in particular for intraoperative tumor margin detection. 
While several objectives must be met to validate their use as rapid diagnostic imaging 
agents in the clinic, this unique and additional feature of silica-gold nanoshells, never 
before thoroughly studied, has been shown. This distinctive characteristic of silica-gold 
nanoshells is expected to evoke numerous opportunities in the field of biomedical 
nanophotonics. 
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CHAPTER 2 
INTRODUCTION 
Currently, breast cancer is the second leading cause of cancer-related deaths in 
women and it accounts for approximately one-third of all cancers diagnosed in women in 
the United States. 1 In order to reduce cancer recurrence and progression, cancerous 
tissue must be completely eliminated, regardless of grade.2 Treatment decisions are, 
therefore, absolutely critical. Although some patients may need to undergo mastectomy, 
which involves complete removal of the entire breast, some patients with less-advanced 
breast cancer may choose breast-conserving surgery. To reduce the likelihood of cancer 
recurrence, it is recommended that patients seeking breast conservation therapy, such as 
lumpectomy, undergo adjuvant radiation treatment. 3 Specifically, Fisher et al. 
determined that lumpectomy (followed by radiation therapy) is just as effective as 
mastectomy as long as the resected tissue specimens contain negative tumor margins. 3 
The accurate delineation of tumor margins is one of the most significant factors in 
cancer recurrence and its importance has been documented for several cancers, including 
breast4,5, brain6,7, prostateS, larynx9, melanoma10-12, urothelial13, ora114-16 and cervical17-19 
cancers. The presence of a positive surgical margin has been associated with lower rates 
in patient survival.2o Due to residual cancer cells being left in many patients that undergo 
breast conservation therapy, as many as 40% of patients have experienced local breast 
cancer recurrence near the site of the original tumor.3 
Current intraoperative tumor margin detection involves the surgeon removing the 
tissue that he/she visually perceives as cancerous (as well as a region of surrounding 
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'perceived' normal tissue) and the tissue being sent to pathology where it undergoes 
further analysis. For tumors that are palpable, the process usually involves inking the 
breast specimen (to designate in situ location) followed by serial sectioning and physical 
measurement between the edge of the tumor and the margin of the resected tissue. If the 
margins appear negative, the sample is further processed by permanent paraffin-
embedded histology. However, if the margins appear positive, suspicious areas typically 
undergo frozen sectioning and histology for microscopic confirmation. For tumors that 
are non-palpable, radiographs are taken of the specimen both before and after serial 
sectioning (and specimen inking). The distance between the tumor and the resected edge 
is measured and the specimen is evaluated grossly. 
During this evaluation, the surgical team waits for a response from the pathologist 
while the patient remains anesthetized. Based on the results, the pathologist contacts the 
surgical team in the operating room and notifies them if enough tissue has been removed 
('negative margin'). On occasion, enough tissue has been excised and the surgical team 
can proceed with suturing the patient. Other times, however, not enough tissue has been 
removed ('positive margin') and the process continues until the histological sample 
shows an adequate tumor margin. Clearly, this current practice of determining tumor 
margins during surgery is expensive and inconvenient. 
Once surgeons are able to achieve clear or negative margins, for which there are 
no histologically visible dysplastic cells surrounding the resected tumor, the primary goal 
of the surgical procedure has been met. Cases for which a positive margin has been 
obtained typically result in continued tissue resection until the margins become negative. 
In some cases, additional tissue removal is not feasible and the procedure terminates with 
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the possibility of residual dysplasic cells remaining in the body cavity. The purpose of 
adjuvant radiation treatment in patients undergoing breast conservation surgery is to 
combat these potential residual cancerous cells and maintain local control.21 
The aforementioned method of tumor margin detection applies only to specialized 
tertiary centers, such as The University of Texas M.D. Anderson Cancer Center 
(MDACC). In community hospitals, however, pathologic analysis of excised tissue does 
not occur until well after the operation is complete. Those patients who subsequently 
present with positive tumor margins must return for an additional surgical procedure to 
remove remaining suspicious tissue, which portends additional risks and costs to the 
patient. Furthermore, the accuracy of breast cancer diagnosis in community hospitals 
needs to be addressed; approximately 10,000 cases of misdiagnoses are estimated to 
occur annually .12 Due to the existing limitations of current intraoperative tumor margin 
detection, there is an opportunity to develop superior diagnostic tools to assist in reducing 
the recurrence and progression of cancer due to inadequate tissue removal during primary 
surgery. 
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CHAPTER 38 
CURRENT METHODS OF MICROSCOPIC BREAST CANCER 
TUMOR MARGIN DETECTION 
3.1 Introduction 
As formerly described, during breast conservation surgery, the surgeon initially 
removes the suspicious breast tissue and, using tactile sensation and visual inspection of 
both the specimen and region of excision, determines if the entire cancerous region has 
been removed. The first intraoperative tumor margin detection, therefore, occurs grossly. 
Used as the only intraoperative tumor margin detection method, gross examination results 
in positive tumor margins roughly 50% of the time.! The identification of any 
microscopic residual cells located at the margin of the excised specimen occurs 
subsequently by a pathology lab. In community hospitals, this typically occurs post-
operatively and is performed by paraffin-embedded histology. Other specialized cancer 
centers, however, perform microscopic tumor margin evaluation while the patient 
remains anesthetized. Regions of the specimen that contain suspicious tumor margins are 
processed immediately, typically by frozen section histology or touch prep cytology. The 
remaining tissue sample is later processed by paraffin-embedded histology, which 
provides the final margin status. 2 
a Adapted from: Bickford LR, Drezek RA, Yu T-K, "Intraoperative techniques and tumor margin status _ 
Room for improvement for cervical cancer patients of childbearing age"; Gynecologic Oncology, Vol. 
10711 S, S 180-186 (2007). 
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3.2 Paramn-Embedded Histology 
While paraffin-embedded histology remains the gold standard of tumor margin 
detection, this method is very lengthy and cannot, therefore, be performed 
intraoperatively. This lengthy process is due to the series of steps necessary for 
adequately preserving the tissue. The tissue samples must first be fixed and then 
prepared for paraffm infiltration by sample dehydration through a series of alcohols. 
Once the samples are embedded in paraffin, they are sectioned with a microtome, which 
serially sections the tissue at a designated thickness. Tissue sections must then be stained 
through a series of additional steps to visualize the cellular morphology of interest. This 
method of tissue processing continues to be the most accepted due to its reliability, ease 
of use, and cost. 3 
3.3 Frozen Section Histology 
Frozen sections are used frequently for their quick, easy, and least labor intensive 
diagnosis3 and have an accuracy as high as 97-99% when compared to paraffin 
histology.4,5 The tissue sample is frozen as quickly as possible and is then sectioned 
using a special microtome called a cryostat. The tissue samples may be fixed or unfixed, 
depending on the preference of the laboratory. After the specimens are sectioned and 
mounted to glass slides, they are traditionally stained with hematoxylin and eosin (H&E), 
which are the most frequently used stains for histology.6 The use of H&E allows cell 
nuclei to be stained a bluelblack color, while the cell cytoplasm and connective tissue 
fibers obtain a pink color. Dysplasic cells are distinguished from their normal cell 
counterparts by their cellular characteristics, including cell and nuclear size, presence of 
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mitoses, and level of differentiation.7 Though historically used as a standard procedure, 
H&E histology for frozen intraoperative tissue analysis has been shown to present several 
limitations. These limitations include difficulties in processing, such as the development 
of artifacts8, as well as sampling error, cost, time needed to achieve diagnosis, reliability 
as a staging modality, and variability of results with level of operator experience.9,10 
Additionally, Black et al. have illustrated that there is not a standard to frozen section 
analysis once the tissue samples have been collected and that what is considered 
'adequate' varies according to surgeon subjectivity.lO 
3.4 Touch-Prep Cytology 
Touch-prep cytology has been proposed as an alternative technique for evaluating 
margin status and has been primarily studied for the diagnosis of breast cancer tumor 
margins.8-9,1l-13 This method has also been referred to as wet-film cytology, cytologic 
smear, and imprint cytology. Much like standard frozen histology, touch-prep cytology 
is regarded as a rapid, simple, and accurate way to determine tumor margins 
intraoperatively. In this method, a glass slide is pressed up against the specimen margins 
in question and cells stick to the slide. This technique is performed for each margin of 
the tissue sample and, after the tissue is imprinted onto glass slides, the slides are fixed 
and stained with H&E prior to being viewed microscopically. The actual specimen is 
additionally inked, sectioned, and stained to verify diagnosis. Studies have shown that 
the accuracy of touch-prep diagnoses varies from 85-99.3%, sensitivity ranges from 80-
96.4%, and specificity ranges from 85-100% when compared to paraffin-embedded 
histology.8,12 As with frozen section preparation, an experienced pathologist is needed to 
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assess tumor margin involvement. However, unlike the use of a cryostat which may 
result in inadequate and unusable tissue sections, loss of tissue is not a concern with the 
touch-prep method. 
Although touch-prep cytology appears to be a superior alternative to frozen 
section analysis, limitations exist that render this method less promising. A major 
limitation of touch prep cytology is that only positive margins can be detected and, 
therefore, the distance between the edge of a negative margin and the edge of the tumor 
cannot be evaluated? Additionally, touch prep cytology does not seem to dramatically 
reduce sample processing time; an average of 15 minutes has been reported for cytologic 
results to become available. 13 This is similar to the amount of time needed to acquire 
results from frozen section histology (based on physical observations at MDACC). 
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CHAPTER4b 
THE POTENTIAL OF MICROSCOPIC, SCATTERING-BASED 
IMAGING SYSTEMS AND CONTRAST AGENTS 
4.1 Introduction 
Medical imaging technologies such as magnetic resonance imaging, 
mammography, and positron emission tomography have revolutionized the detection of 
cancer over the last thirty years. Although these tools are invaluable for understanding 
the normal structure of various tissues and associated irregularities, being able to 
visualize cancerous abnormalities at the microscopic level is necessary for adequate 
delineation of tumor margins and thus, prevention of recurrent disease. Various research 
laboratories are already looking at the potential of using microscopic optical imaging 
techniques to diagnose oral 1-4, cervicaI4-1o, skinll, colon and gastrointestinaI12-15, and 
breast cancers16-22• While several of these laboratories are optimizing and developing 
instrumentation for the direct imaging of tissues, others are also considering the benefits 
of utilizing both exogeneous contrast agents in tandem with optical tools. One advantage 
of using exogenous contrast agents is that detection limits can be significantly improved 
beyond what is capable with optical instrumentation alone. Additionally, some 
exogenous contrast agents can be targeted to biomarkers which are overexpressed during 
b Adapted from: Bickford LR, Day ES, Hu Y, Sun J, Fu K, Chang J, Lewinski NA, Yu T-K, Drezek RA. 
"Biomedical Applications of Multi-functional Silica-Based Gold Nanoshells " in Biomedical 
Nanotechnology: Materials for Nanomedicine, edited by Mansoor M. Amiji, RPh, PhD, and Vladimir P. 
Torchilin, DSc, PhD (pan Stanford Publishing). In press (2010). 
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the multi stages of cancer progression. By combining both contrast agents and imaging 
devices, these biomarkers may be used as tools for intraoperative tumor margin detection, 
which will require identifying malignant cells among heterogeneous tissue. 
Currently, research interest centered on developing optical techniques that 
combine both contrast agents and imaging devices is focused on diagnostic applications 
in the near-infrared (NIR) spectral region.23-27 Since the major absorbers in biological 
tissue are water, hemoglobin and oxy-hemoglobin, the high absorption peaks of these 
substances must be avoided so that potentially greater signals can be detected for tissue-
based diagnostics.27 Figure 4.1 illustrates the absorption spectra of tissue absorbers from 
the visible to the NIR region. Hemoglobin mainly absorbs in wavelength ranges lower 
than 650 nm, while water mainly absorbs in wavelength ranges greater than 900 nm. 
Thus, the NIR window of 650 nm - 900 nm is ideal for biological imaging applications.27 
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Figure 4.1. Spectra of major tissue absorbers showing that the NIR region (650<"-<900) 
is ideal for in vivo diagnostic application. Adapted from Reference 27. 
Accordingly, utilizing exogenous contrast agents that can scatter or absorb light in 
the NIR window has become increasingly critical for biomedical researchers. Gold-based 
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nanoparticles, specifically, have gained increased attention in the area of biomedical 
diagnostics because of their great potential as such imaging contrast agents.z2-26 Thus far, 
the most predominantly and thoroughly studied gold-based nanoparticles include 
nanoshells21-26,28-34, gold colloid35-38, and nanorods39-45. For the purposes of this thesis, I 
have chosen to focus on the use of silica-based gold nanoshells, which have previously 
demonstrated effectiveness as diagnostic imaging agents for HER2-overexpressing breast 
cancer cells.22,23,26 
In order to evaluate contrast facilitated by gold nanoparticles, scattering- and 
absorption-sensitive optical tools must be employed. Absorption-sensitive tools are 
commonly associated with therapeutic applications and will not be considered here. 
Scattering-sensitive devices, meanwhile, are typically used for achieving real-time 
diagnostic results. Although these tools have included darkfield microscopy, optical 
coherence tomography (OCT), and reflectance confocal microscopy (RCM) , darkfield 
microscopy and RCM are the two scattering-based imaging systems which will be 
discussed as they are particularly advantageous for visualizing the surface of a particular 
tissue of interest. 
4.2 Darkfield Microscopy 
Darkfield microscopy is ideal for imaging strongly-scattering specimens, such as 
biological cells and nanoparticles, that otherwise have low contrast under standard 
brightfield microscopy. Under darkfield microscopy, images are formed only by the light 
that is scattered from the subject of interest.46 This is possible in part because of a 
specialized condenser (or stop) that prevents a solid cone of transmitted light from 
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entering the objective lens, such as in brightfield microscopy (Figure 4.2). In darkfield 
microscopy, the numerical aperture of the condenser is greater than the numerical 
aperture of the objective. As can be seen in Figure 4.3, when imaging the single-celled 
green alga Chlamydomonas with darkfield microscopy under specific illumination 
conditions, the cells appears bright against a dark background. Visualization of the same 
cells under standard brightfield microscopy, meanwhile, produces a very different image 
in which the contrast between the alga and background is more difficult to distinguish. 
Darkfield Brightfield 
Figure 4.2. Diagram comparing darkfield and brightfield microscopy. Republished from 
Reference 46. 
When imaging cells labeled with immunotargeted nanoshells under darkfield 
microscopy, the contrast of the cells is enhanced by the attached nanoshells due to the 
strong scattering signal from the nanoshells, as shown in Figure 4.4.26 The labeling of 
cells with nanoshells significantly improves the image contrast in comparison with those 
images taken of cells without nanoshells. 
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Figure 4.3. (a.) Brightfield and (b.) darkfield images of the single-celled green alga 
Chlamydomonas. Reproduced from http://www . wsu.edul~omoto/paperslFig2.html; 
accessed on 09118/2010. 
Figure 4.4. Darkfield microscopy images of HER2-positive SK-BR-3 cells with (a) 
specific anti-HER2-nanoshell targeting, (b) non-specific anti-IgG-nanoshell targeting, 
and ( c) without targeting. Republished from Reference 26. 
4.3 Reflectance Confocal Microscopy 
Reflectance confocal microscopy is an imaging tool that allows visualization of 
scattering-based structures at and beyond the surface. By employing the use of point 
illumination and a specialized pinhole, out-of-focus light can be rejected thus providing a 
high resolution image of specimens that are thicker than the focal plane (Figure 4.5). 
Confocal microscopy can also be used to generate 3-D images based on a reconstruction 
of multiple images taken at various depths throughout a specimen. This imaging modality 
has found applications in fluorescence imaging, as well as reflectance imaging. Unlike 
conventional confocal microscopy, which relies on the excitation of endogenous or 
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exogenous fluorophores, RCM involves the collection of backscattered light at different 
depths from the tissue of interest, where the confocal pinhole is used to eliminate signals 
from the out-of-focus planes. Accessibility issues have limited the use of conventional 
£ 1 . h k' 4748 49 l' d 50 R d con oca mICroscopy to areas as t e s In ' ,cornea , Ip an tongue . ecent avances 
in fiber optics, however, have made it possible to integrate the components of confocal 
microscopy into an optical fiber bundle with a miniaturized objective, enabling access to 
other tissue sites, such as the cervix.51 -53 • 
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Figure 4.5. Schematic of a confocal microscope. Reproduced from 
http://www .mikroskopie. org/2008/0 1 126/types-of-confocal-microscopy 1141; accessed on 
08125/2010. 
The use of RCM as a device for assessing tumor margins has previously been 
shown by Chen et al.54 The authors looked at the use of RCM for assessing lentigo 
maligna melanoma tumor margins in vivo. Lentigo maligna melanoma is a noninvasive 
melanoma that is sometimes difficult to assess due to photothermal damage already 
present on the skin surface. In this study, the authors used RCM to identify the 
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superficial extent of the tumor and performed punch biopsies and standard H&E 
histology on the samples to confirm their results. The performance of the confocal 
microscope was in agreement with the histological evaluation and on follow-up one year 
later, the patient displayed no evidence of tumor recurrence. Although this study was 
performed on only one patient, the findings reinforce the use of confocal microscopy as a 
possible strategy for determining tumor margin involvement. 
More recently, Parrish et al. demonstrated the use of RCM to characterize 
mammary ductal structures of wild-type mice and genetically engineered mice with 
ductal carcinoma in sitU. 18 In this study, the researchers utilized acetic acid as a contrast 
agent in order to enhance visible cellular structures. As can be seen in Figure 4.6, the 
application of acetic acid to both normal and cancerous mammary tissues resulted in 
enhanced contrast for the cancerous sample under RCM. Normal tissue appears 
significantly less reflective. The studies demonstrate that RCM may be a tool for rapid 
and accurate analysis of mammary gland structures. 
Reflectance Confocal 
Microscopy H&E 
Mammary Gland 
WhoJe Mount 
Figure 4.6. Comparison of RCM images with corresponding H&E stained sections of 
mammary gland tissues. A-C: Normal mouse; D-F: Genetically engineered mouse with 
ductal carcinoma in situ. C,F: Whole mount images demonstrate lateral budding (black 
arrows). 5% acetic acid was used as a contrast agent. Adapted from Reference 18. 
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Tilli et al. furthered this application to the characterization of human breast cancer 
biopsy samples.2o Again, by implementing the use of acetic acid as a contrast agent, the 
characteristic features associated with normal and malignant cells (such as nuclear 
morphology and cancer cell invasion) could be discerned. and compared well with 
corresponding H&E stained sections. Although the results of this study support the use 
of ReM as a tool for rapid and accurate analysis of mammary gland structures in tandem 
with acetic acid, the authors indicated that the use of different contrast agents may incur 
greater resolution and increased detection of cancer cells throughout their multistage 
progression. 
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CHAPTER5C 
PROPERTIES OF SILICA-GOLD NANOSHELLS 
5.1 Introduction 
As mentioned previously, various gold-based nanoparticies have been explored as 
agents for biomedical applications. For the ultimate purpose of rapid tumor margin 
detection, gold nanoshells will act as optical contrast agents that are specifically targeted 
to molecular surface markers of breast cancer cells that can be used directly in the 
operating room to enhance current detection methods. Nanoshells are advantageous for 
biomedical applications because they are highly biocompatible, they possess ideal optical 
properties for imaging, and they can be readily conjugated with antibodies that bind to 
specific markers that are overexpressed in certain types of cancer. 1-3 
Based on the core-to-shell ratio, nanoshells can be designed to preferentially 
absorb or scatter light. Absorbed energy is dissipated in the form of heat, which enables 
gold nanoshells to be used for applications such as photo-thermal therapy.4 Meanwhile, 
scattered light permits nanoshells to serve as contrast agents by enhancing optical 
contrast for several imaging applications, such as the aforementioned darkfield 
microscopy5, reflectance confocal microscopy6, and optical coherence tomography3,7. 
The optical extinction spectra of nanoshells can be calculated by employing the Mie 
C Adapted from: Bickford LR, Day ES, Hu Y, Sun J, Fu K, Chang J, Lewinski NA, Yu T-K, Drezek RA. 
"Biomedical Applications of Multi-functional Silica-Based Gold Nanoshells " in Biomedical 
Nanotechnology: Materials for Nanomedicine, edited by Mansoor M. Amiji, RPh, PhD, and Vladimir P. 
Torchilin, DSc, PhD (Pan Stanford Publishing). In press (2010). 
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solution to Maxwell's equations for concentric spheres.8,9 Energy-level-dependent gold 
properties can be obtained from Johnson and ChriSty.1O 
Figure 5.1 illustrates the extinction, absorption, and scattering results from sample 
calculations performed for a common-sized nanoshell with a core diameter of 260 nm 
and a shell thickness of 20 nm immersed in water. The extinction peak observed in Figure 
5.1 is also known as the plasmonic resonance of the nanoshell. Plasmon resonances are a 
result of the oscillation of the incompressible electron gas in the conducting gold shell. 
Such resonance enhance the amount of the scattered or absorbed light, which may yield 
an extinction cross-section several times larger than the physical dimension of the particle 
itself. 
One particularly unique feature of nanoshells is their agile optical tunability. This 
allows one to engineer the nanoshell extinction peak to coincide with the NIR optical 
window for biological applications. The optical tunability can best be understood both 
qualitatively and quantitatively by the theory of plasmon hybridization between shell and 
cavity. I I The shell thickness determines the strength of the interaction between the 
plasmons on the inner and outer surface of the gold shell. Jain et a1. recently explained 
that the plasmon resonant wavelength decays near-exponentially as the interparticle gap 
(ie. shell thickness) is scaled by the particle size. 12 This is illustrated in Figure 5.2 with 
the spectra of five groups of nanoshells that have an identical outer diameter but distinct 
core diameter-to-shell thickness ratios. The extinction peak is readily tuned in the entire 
visible-NIR spectrum without changing the overall particle size. 
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Figure 5.1. Spectra for nanoshells with a silica core diameter of 260 nm and a shell 
thickness of20 nm suspended in water. Image provided courtesy ofYing Hu. 
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Figure 5.2. Extinction spectra for different groups of nanoshells in water, all with a total 
diameter of 130 nm. From left to right, the inner core diameter changes as follows: 80, 
100, 110, 114, and 118 nm. Image provided courtesy ofYing Hu. 
5.2 N anoshell Fabrication 
As previously published by Loo et al. 13, the synthetic protocol developed for the 
fabrication of gold nanoshells consists of three basic steps: 
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I. grow or obtain silica nanoparticles dispersed in solution, 
II. attach very small (1-2 nm) metal "seed" colloids to the surface of the 
nanoparticles via molecular linkages; these seed colloids cover the dielectric 
nanoparticle surfaces with a discontinuous metal colloid layer, 
III. grow additional metal onto the "seed" metal colloid adsorbates via chemical 
reduction solution. 
Various stages in the growth of a gold metallic shell onto a functionalized silica 
nanoparticle are shown in Figure 5.3 . 
First, cores of silica nanoparticles are fabricated as described by Stober et al. I 4 in 
which tetraethyl orthosilicate (TEOS) is reduced in ammonium hydroxide (N~OH) in 
ethanol. Next, the silica surface is aminated by reaction with aminopropyltriethoxysilane 
(APTES) in ethanol. Gold shells are then grown using the method of Duff et al. I S Briefly, 
small gold colloid (1-3 nm) is adsorbed onto the animated silica nanoparticle surface. 
More gold is then reduced onto these colloid nucleation sites using potassium carbonate 
and hydrogen tetrachloroaurate trihydrate (HAuC4 3H20) in the presence of 
formaldehyde. Gold nanoshell formation and dimensions are typically assessed with a 
UV -VIS spectrophotometer and scanning electron microscopy (SEM). The original 
description of metallodielectric nanoshell synthesis can be found in Oldenburg et al. I6 
Figure 5.3. Transmission electron microscope images of gold/silica nanoshells during 
shell growth. Republished from Reference 13. 
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5.3 Nanoshell-Antibody Conjugation 
Loo et. al. l3 formerly introduced the history of bioconjugation as it pertains to 
gold nanoshells as well as a description of how nanoshells are conjugated to other 
biological molecules. In order to conjugate antibodies to nanoshells, an ortho-pyridyl-
disulfide-n-hydroxysuccinimide polyethylene glycol (PEG) polymer (OPSS-PEG-NHS) 
is used to tether antibodies onto the surfaces of the gold nanoshells. The 
amidohydroxysuccinimide group (NHS) enables conjugation of the PEG linker to the 
antibodies through amide linkages; the remaining end of the PEG linker, OPSS, allows 
binding to the nanoshell gold surfaces through sulfur groups. Using sodium bicarbonate, 
OPSS-PEG-NHS is typically resuspended to a volume equal to that of either specific or 
non-specific antibodies. The reaction is allowed to proceed on ice overnight. Excess 
unbound polymer may then be removed by membrane dialysis. PEGylated antibody is 
then added to the nanoshells for at least 1 hour to facilitate targeting. Following antibody 
conjugation, nanoshell surfaces are further modified with PEG-thiol (PEG-SH) to block 
non-specific adsorption sites and to enhance biocompatibility. 
5.4 Conclusion 
Silica-based gold nanoshells offer exciting optical properties that are not 
otherwise conventionally available, including large extinction cross-sections and flexible 
optical tunability. These characteristics render gold nanoshells as exceptional optical 
agents for numerous biomedical practices. For this thesis, nanoshells will be conjugated 
to anti-HER2 antibodies. This particular antibody has been selected as a model surface 
tumor target due to its association with more aggressive breast cancers seen in 15-25% of 
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otherwise conventionally available, including large extinction cross-sections and flexible 
optical tunability. These characteristics render gold nanoshells as exceptional optical 
agents for numerous biomedical practices. For this thesis, nanoshells will be conjugated 
to anti-HER2 antibodies. This particular antibody has been selected as a model surface 
tumor target due to its association with more aggressive breast cancers seen in 15-25% of 
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all breast cancer cases. 17 Additionally, studies in our laboratory have previously 
demonstrated the effectiveness of using nanoshells as diagnostic imaging agents for 
HER2-overexpressing cancer cells. 1,2,5 Nanoshells will further be evaluated at the tissue-
level for more clinically-relevant applications. Based on the results of this research, the 
combined use of nanoparticles and optical imaging tools may offer promise for rapid 
intraoperative tumor detection. 
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CHAPTER6d 
INVESTIGATE THE USE OF GOLD NANOSHELLS AS RAPID 
DIAGNOSTIC IMAGING AGENTS IN VITRO 
The previous chapters have introduced the need for superior diagnostic imaging 
tools for intraoperative tumor margin detection and have provided a foundation for 
understanding key properties of silica-based gold nanoshells and the imaging systems 
capable of observing their scattering-signatures. In this chapter, the aforementioned 
backgrounds come together in order to examine the efficacy of using gold nanoshells as 
rapid diagnostic imaging agents in the most fundamental and imperative proof of concept 
experiments: in vitro cell studies. 
6.1 Introduction 
Several nanoparticles have been explored for potential applications in cancer 
diagnosis, including nanoshells l -4, gold colloids,6, quantum dots7,8, carbon dots9, 
nanorods lO-12 and nanocrystals13• For in vivo applications, several steps will need to be 
taken to ensure the safe delivery of nanoparticles before they can be used in a clinical 
setting. However, several opportunities still exist for in vitro applications in which the 
cytotoxicity of nanoparticles is immaterial. Numerous in vitro technologies that have 
shown promise for point-of-care diagnostic testing may allow clinicians to provide user-
d Adapted from: Bickford LR, Chang J, Fu K, Sun J, Hu Y, Gobin AM, Yu T-K, Drezek RA, "Evaluation 
of Immunotargeted Gold Nanoshells as Rapid Diagnostic Imaging Agents for HER2-0verexpressing Breast 
Cancer Cells: A Time-Based Analysis"; NanoBiotechnology, 4(1-4), 1-8 (2008). 
41 
CHAPTER6d 
INVESTIGATE THE USE OF GOLD NANOSHELLS AS RAPID 
DIAGNOSTIC I AGING AGENTS IN VITRO 
The previous chapters have introduced the need for superior diagnostic imaging 
tools for intraoperative tumor margin detection and have provided a foundation for 
understanding key properties of silica-based gold nanoshells and the imaging systems 
capable of observing their scattering-signatures. In this chapter, the aforementioned 
backgrounds come together in order to examine the efficacy of using gold nanoshells as 
rapid diagnostic imaging agents in the most fundamental and imperative proof of concept 
experiments: in vitro cell studies. 
6.1 Introduction 
Several nanoparticles have been explored for potential applications in cancer 
diagnosis, including nanoshells l -4, gold colloids,6, quantum dots7,8, carbon dots9, 
nanorods lO-12 and nanocrystals13 • For in vivo applications, several steps will need to be 
taken to ensure the safe delivery of nanoparticles before they can be used in a clinical 
setting. However, several opportunities still exist for in vitro applications in which the 
cytotoxicity of nanoparticles is immaterial. Numerous in vitro technologies that have 
shown promise for point-of-care diagnostic testing may allow clinicians to provide user-
d Adapted from: Bickford LR, Chang J, Fu K, Sun J, Hu Y, Gobin AM, Yu T-K, Drezek RA, "Evaluation 
of Immunotargeted Gold Nanoshells as Rapid Diagnostic Imaging Agents for HER2-0verexpressing Breast 
Cancer Cells: A Time-Based Analysis"; NanoBiotechnology, 4(1-4), 1-8 (2008). 
41 
friendly, cost effective, and rapid results at the patient bedside. Currently, these 
technologies involve analyzing biological fluids to detect DNA or protein amplification 
through the use of micro arrays or biochip devices14-16. In addition to fluid-based 
modalities, these microscopic advancements can also be used to analyze larger biological 
components, such as excised tumor specimens, for cancer screening and diagnosis. One 
particular area of application is the diagnosis of cancer from biopsy samples. For 
example, after a breast biopsy, the specimen is sent to a pathology laboratory where it is 
processed and examined microscopically for morphological abnormalities and sometimes 
analyzed for the presence of molecular biomarkers of disease, such as hormone receptor 
expression 17. This process can take up to several days, during which the patient must 
cope with the fear of an unknown diagnosis and the potential of treatment delay. Mojica 
et al. showed that delays between initial breast cancer symptoms and treatment are 
associated with lower survival rates18. Consequently, delays in breast cancer diagnosis 
top the list of liability claims made against physicians19. 
Another area of opportunity for advancement 10 point-of-care microscopic 
analysis of tumor specimens involves the assessment of intraoperative tumor margins. 
During a lumpectomy, for instance, the surgeon removes the suspected cancerous lesion 
with a margin of normal tissue. Judgment of the width of this margin is largely based on 
tactile sensation and visible, macroscopic abnormalities. In advanced hospital systems, 
the sample is excised and immediately subjected to pathologic analysis to ensure the 
surgical margins are tumor-free before the procedure is completed. The need to achieve 
negative margins is critical to minimizing cancer recurrence and progression, particularly 
for patients undergoing breast conservation therapy2o. The presence of a positive surgical 
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margin has been associated with lower rates in patient survival18• Due to residual cancer 
cells being left in many patients that undergo breast conservation therapy, as many as 
40% of patients have experienced local breast cancer recurrence near the site of the 
original tumOil. Positive margins in a surgical specimen, therefore, necessitate the 
resection of additional tissue until the margins do not contain tumor. Even if the 
specimens are examined immediately, this extends the period of anesthesia and hence 
increases both the cost and risk to the patient. Furthermore, many county hospitals must 
by necessity process tissue samples after the surgery is completed. In that case, the 
identification of positive surgical margins requires that the patient undergo another 
surgical procedure to excise the remaining tissue, which further delays the start of 
adjuvant treatment and increases the risk of cancer recurrence and subsequent patient 
mortality. 
With the expansion of nanotechnology-driven research, opportunities for the use 
of fast and accurate diagnostic tests outside of the hospital laboratory are likely to 
increase. To realistically use nanopartic1es as a point-of-care tool for the immediate 
assessment of key cancer gene signatures in excised tissue samples, the time needed to 
achieve optical contrast must be minimized. Thus far, few published reports have 
focused on minimizing the time needed to achieve suitable contrast of cancer cells 
incubated with nanoparticles. Previous studies demonstrating the effectiveness of using 
gold-based nanopartic1es targeted to extracellular cancer biomarkers have involved 
. b·· . fr 30 90· 1 35610-12 mcu atIon tImes rangmg om to mmutes ' , , , . The objective of this study 
was to demonstrate the feasibility of using gold nanoshells targeted to anti-HER2 
antibodies to achieve sufficient optical contrast in a HER2-overexpressing breast cancer 
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cell line (SK-BR-3) after a series of incubation times. Overexpression of the HER2 
receptor is associated with greater cancer progression and is seen in approximately 15-
25% of all breast cancer cases 17. The nanoshells, made of dielectric silica particles 
covered with a thin gold shell, were fabricated to scatter strongly in the near-infrared 
spectrum through manipulation of the silica core:gold shell ratio. We compared the 
contrast that could be achieved by incubating the nanoshells with both normal and 
cancerous cells. Our results demonstrate that gold nanoshells targeted to this cell-surface 
marker can produce enhanced contrast after only 5 minutes of incubation. This proof of 
concept supports the initial feasibility of using gold nanoshells for potential point-of-care 
diagnostic applications. 
6.2 Materials and Methods 
6.2.1 Nanoshell Fabrication 
Nanoshells were developed and bioconjugated as described in Chapter 5. The 
final silica particles were measured by scanning electron microscopy (SEM) to obtain the 
average silica core diameter of 254 nm. The spectrum of the completed nanoshells was 
analyzed with a UV-vis spectrophotometer (Varian Cary 300). The relationship between 
the extinction spectrum obtained by UV -vis spectroscopy and that obtained by 
application of the Mie scattering theory can be used to approximate the size of the 
nanoparticles in solution (Figure 6.1). Subsequently, Mie Theory can be used to derive 
the absorption, scattering, and extinction coefficients for nanoparticles of a specific size, 
and a standard known concentration can be acquired for a particular optical density. In 
addition to using Mie scattering theory for multilayer spheres, we also used SEM to 
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confirm the size of the nanoshells. The nanoshells used in this study had an average 
diameter of 292 nm, a peak surface plasmon resonance at 778 nm and a concentration of 
approximately 1.6x 109 particles/mL. 
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Figure 6.1. Measured spectra of nanoshells (core radius 127 nm, shell thickness 19 nm) 
as compared with that estimated using the Mie scattering theory; the insert depicts the 
corresponding image from scanning electron microscopy. Scale bar represents 500 nm. 
6.2.2 Nanoshell Surface Modification 
To target the prepared nanopartic1es to molecular markers associated with HER2-
overexpression, antibodies were first prepared by methods described in Chapter 5. 
Briefly, anti-HER2 antibodies (C-erbB-2/HER-2Ineu Ab-4, Lab Vision Corporation) 
were conjugated to the heterobifunctionalized polyethylene glycol linker orthopyridyl-
disulfide-PEG-N-hydroxysuccinimide ester (OPSS-PEG-NHS, MW 2kD, 
CreativeBiochem Laboratories) by reaction at a molar ratio of 1:3 in sodium bicarbonate 
(100 mM, pH 8.5) overnight on ice. Aliquots were stored at -80°C. The nanoshells 
(1.6 x 109 partic1es/mL) were incubated with the prepared anti-HER2-PEG solution (0.4 
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mg/mL) for 1 hour at 4°C. The newly conjugated nanoshells were subsequently 
incubated with a 10 )lM polyethylene glycol-thiol solution (PEG-SR, MW = 5kD, 
Nektar) for 2 additional hours at 4°C, which stabilized the nanoshells by blocking any 
unoccupied adsorption sites. The nanoshells were then centrifuged to remove unbound 
antibodies, resuspended in ultrapure water, and stored at room temperature until use. 
Before being incubated with cells, the nanoshell solution was supplemented with bovine 
serum albumin (BSA) and phosphate-buffered saline (PBS) at final concentrations of 1 % 
each. 
6.2.3 Preparation of Cells 
Two cell types were analyzed for this study: the RER2-overexpressing epithelial 
breast cancer cell line SK-BR-3 and the normal mammary epithelial cell line MCFI0A 
(American Type Culture Collection). The SK-BR-3 cells were grown in McCoy's 5A 
medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin and maintained at 37°C in a 5% C02 atmosphere. The MCFIOA cells were 
cultured in Mammary Epithelial Basal Medium (MEBM) supplemented with a BulletKit 
(Clonetics) and also maintained at 37°C in 5% C02. Both cell lines were grown in 25-
cm2 culture flasks until confluent. At that time, cells were rinsed once with Ix PBS and 
incubated with trypsin-EDT A for 5 minutes at 37°C to detach the cells from the substrate, 
after which trypsin was neutralized with the appropriate medium and the cells were 
counted. Approximately 6xl05 cells were placed in each of four conical tubes per cell 
line for each time point under investigation. The cells were then centrifuged at 115 x g 
for 3 minutes. For each cell line and each time point of interest, three cell pellets were 
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resuspended in the bioconjugate-nanoshell solution and one was resuspended in an equal 
amount of PBS as a control. The nanoshell-cell suspensions and controls were then 
incubated in a hybridization chamber (VWR International) at 37°C and a motor speed of 
7 rpm for 5, 10,30, or 60 minutes. After incubation, the suspensions were centrifuged at 
115 x g for 3 minutes and the unbound nanoshells were collected with a pipette. Cells 
were then rinsed once with Ix PBS, centrifuged, and the unbound nanoshells were again 
collected. A small volume (5 J.lL) of 10% glucose mixed with PBS was added to the 
remaining cell pellets to prevent cell death during imaging. Approximately 7 J.lL of each 
pellet was placed on a glass slide and coverslipped for immediate microscopic analysis. 
6.2.4 Darkfield Imaging and Processing 
Images of the two cell types incubated with nanoshells were obtained with a Zeiss 
Axioskop 2 darkfield microscope outfitted with a color camera (Zeiss AxioCam MRc5). 
Darkfield microscopy depends on light scattering to achieve contrast. All images were 
taken under the same lighting conditions and magnification (20x). Optical intensity was 
quantified by using a MATLAB code. Based on this code, an image with a value of 0 
was designated pure black and that with a value of 255 pure white. An increase in 
intensity, therefore, corresponded to an image with a higher numerical value. Average 
intensity values for each time point and each cell line were calculated from 10 
independent cell samples that were devoid of scattering influences from neighboring cells 
and unbound nanoshells. Sample normality was assessed by using Minitab to evaluate 
the error distribution for all data points. A normal probability plot of the residuals 
verified that the samples followed a normal distribution (data not shown). F-tests were 
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pellet was placed on a glass slide and coverslipped for immediate microscopic analysis. 
6.2.4 Darkfleld Imaging and Processing 
Images of the two cell types incubated with nanoshells were obtained with a Zeiss 
Axioskop 2 darkfield microscope outfitted with a color camera (Zeiss AxioCam MRc5). 
Darkfield microscopy depends on light scattering to achieve contrast. All images were 
taken under the same lighting conditions and magnification (20x). Optical intensity was 
quantified by using a MATLAB code. Based on this code, an image with a value of 0 
was designated pure black and that with a value of 255 pure white. An increase in 
intensity, therefore, corresponded to an image with a higher numerical value. Average 
intensity values for each time point and each cell line were calculated from 10 
independent cell samples that were devoid of scattering influences from neighboring cells 
and unbound nanoshells. Sample normality was assessed by using Minitab to evaluate 
the error distribution for all data points. A normal probability plot of the residuals 
verified that the samples followed a normal distribution (data not shown). F-tests were 
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also used to determine the equality of variance before applying two-tailed paired 
Student's t-tests to evaluate significance. 
6.2.5 Derivation of Bound Nanoshell Concentration Using Spectroscopy 
According to the Beer-Lambert law, the absorbance of particles in solution is 
directly related to the concentration of those particles in that solution. To validate the 
ability of spectroscopy to predict the concentration of a solution of nanoshells of known 
size, we used linear regression analysis. Nanoshells of known concentration, based on 
the Mie Theory calculations, were serially diluted and the corresponding peak absorbance 
values were measured. We considered a concentration of approximately 2.0x 109 
particles/mL (optical density = 2.4) as a 100x concentration. From this analysis, an 
equation relating the peak absorbance (independent variable) to each known nanoshell 
concentration (dependent variable) was used to approximate the number of nanoparticles 
in subsequent solutions of unknown concentration. This derivation was necessary to 
calculate the approximate number of bound nanoparticles per cell at the different time 
points. 
To determine and compare the number of nanoshells bound after 5 minutes and 
60 minutes of incubation, the collected unbound nanoshells were centrifuged at 255 x g 
for 20 minutes, resuspended in ultrapure water, transferred to cuvettes and sonicated 
briefly before being measured with a UV -vis spectrophotometer. The spectrum was 
recorded and the peak absorbance documented for each sample. Based on the original 
concentration of nanoshells, the number of cells used, and the concentration of the 
collected unbound nanoshells, the approximate number of nanoshells bound to each 
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cancer cell was derived. An F-test was also used to detennine the equality of variance 
before applying a two-tailed paired Student's t-test to evaluate significance. 
6.3 Results and Discussion 
We evaluated the contrast that could be achieved by incubating nanoshells 
targeted to HER2 receptors with nonnal breast epithelial cells (MCFIOA) or breast 
cancer cells (SK-BR-3) for four intervals: 5, 10,30, and 60 minutes. All procedures were 
done with triplicate samples and included a control condition (cells to which no 
nanoshells had been added). Figures 6.2 and 6.3 illustrate original and enlarged images 
obtained at all four time points for both cells lines and for cells incubated without 
nanoshells (designated as 0 minutes). Because the optical peak resonance for the 
fabricated nanoparticles occurred at 778 nm, the nanoshells scattered strongly in the near-
infrared range and could be visualized under darkfield illumination as red particles. 
Qualitative assessment of the imaging results revealed that the MCFIOA cells showed 
little enhanced scattering at any period of incubation with the bioconjugate-nanoshell 
solution compared with both controls or the cancer cells. However, the SK-BR-3 cancer 
cells showed enhanced contrast after as little as 5 minutes of incubation. Typically, SK-
BR-3 cells express about 8x105 receptors per cell and nonnal MCFIOA cells about 
I x 104 ?2,23 The targeted bioconjugated nanoshells apparently bound to cell surface 
receptors on both cell types; however, because the cancer cells had higher numbers of 
receptors, the contrast that could be achieved was considerably greater with those HER2-
overexpressing cells. Other evidence of the superior contrast achieved with the SK-BR-3 
cells was apparent from the difference in the numbers of unbound nanoshells between the 
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MCFIOA SK-BR-3 
Figure 6.2. Darkfield images of MCFIOA and SK-BR-3 cells incubated with 
bioconjugated nanoshells for the indicated times. Images were obtained at 20x. Scale bar 
represents 125 J.!m. 
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Figure 6.2. Darkfield images of CF10A and SK-BR-3 cells incubated with 
bioconjugated nanoshells for the indicated times. Images were obtained at 20x. Scale bar 
represents 125 ~m. 
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two cell types. In the images of the MCFIOA cells, several unbound nanoshells could be 
seen between cells despite our attempts at removing unbound nanoshells and rinsing the 
cells. Considerably fewer such nanoshells were present in the SK-BR-3-nanoshell 
images (Figure 6.2). 
MCFIOA SK-BR-3 
Figure 6.3. Enlarged darkfield images ofMCF10A and SK-BR-3 cells incubated with the 
bioconjugated nanoshells for the indicated times. Original images taken at 20x. Scale 
bar represents 20 Jlm. 
To quantitatively assess the increase in contrast between the normal and 
cancerous cells at each time point, we used a MA TLAB code to evaluate the average 
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intensity 10 cells from each condition; an intensity value of 0 was considered pure black 
and 255 pure white. Statistical analyses indicated no difference between either cell type 
incubated with only PBS (the control condition) (P>O.I). However, differences between 
the MCFI0A cells and the SK-BR-3 cells were significant at all four incubation times 
(P<O.OOI) (Figure 6.4). An additional analysis of variance showed no differences in the 
mean intensity of the SK-BR-3 cells at any of the four incubation times (P>0.5). 
90 
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Figure 6.4. Mean quantitative intensity values for samples of MCF 1 OA and SKBR3 cells 
incubated with nanoshells for the indicated times. Differences between cell types 
incubated without nanoshells were not statistically significant (P>O.I, n=10). Differences 
between cell types incubated with nanoshells were statistically significant at all time 
points (P<O.OO 1, n= 1 0). Error bars indicate standard deviations. 
To further compare the differences between contrast that could be achieved at 5 
minutes and 60 minutes for the SK-BR-3 cells, we examined the number of bound 
nanoshells at both time points. To do so, we first developed a simple UV-vis 
spectroscopy method to determine the concentration of nanoshells in solution. On the 
basis of dilutions of known nanoshell concentrations, we used linear regression to 
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estimate the concentration of nanoshells in a given solution (Figure 6.5). We confirmed 
the existence of a linear relationship between absorbance and corresponding 
concentration of nanoshells for concentrations ranging from 9.8xl07 to 2.0x109 
particles/mL. With a goodness-of-fit (R2) value of 0.986, we concluded that the 
absorbance accurately predicts the concentration of an unknown suspension of 
nanoparticles that falls within this range. 
2.5 
2 
~ 
u 
1:1 1.5 ~ 
~ 
... 
<:I 
'" ~ 
.,.'---- ... ~,,' .......... ~. 
... " 
,."""" ........................... "' .. 
//~ ........ . 
",' ,,' 
0.5 .......... ..... ...... - _ ....... : •• ,0' ._.~ ._' -'_. _. _'''' ........... .." . .,..-.-
400 500 600 700 800 900 
~ 2.50E+09 
~ 
~ 2.00E+09 
u 
::: 
.. l 1.50E+09 
-
= 
i ~ 5.00E+08 
~ 
Wavelength (nm) 
R2 = 0.986 
-lOOx 
---- 80x 
·······60x 
-.-.- 30x 
- .. _. lOx 
5x 
:! 1.00E+09
1 
a O.OOE+OO +-------,,------.---,----,------, 
o 0.5 1 1.5 2 2.5 
Absorbance 
Figure 6.5. Top, spectra of serial dilutions of known nanoshells concentrations in 
suspension. Bottom, linear regression analysis of known nanoshell concentrations vs. the 
corresponding peak absorbance values. 
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We next used this relationship between absorbance and concentration to measure 
the absorbance of unbound nanoshells collected after incubation and cell rinsing and 
subsequently resuspended in a volume of water equal to that of the diluted samples of 
known concentration. Knowing the initial number of nanoshells and cells, we could 
derive the approximate number of nanoshells bound to each cell, which we did for the 
triplicate samples of nanoshells plus cells after 5 minutes and 60 minutes of incubation. 
At 5 minutes of incubation, 1593 ± 121 nanoshells were bound per cell; at 60 minutes, 
that range was 1686 ± 40 nanoshells per cell (P>O.I, not significant) (Figure 6.6). Thus, 
roughly 95% of the binding noted at 60 minutes had occurred within the first 5 minutes of 
incubation. Our imaging results suggest that this 5% difference did not seem to affect 
contrast. 
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Figure 6.6. Number of nanoshells bound per SK-BR-3 cell after 5 minutes and 60 
minutes of incubation. Values shown are the means of triplicate measurements. Error 
bars indicate standard deviations. 
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6.4 Conclusions 
These findings support the proof of concept that optical contrast of HER2-
overexpressing breast cancer cells can be achieved by brief periods of incubating those 
cells with nanoshells. Although the ability to detect malignancy by such means is critical 
for in vivo applications and for in vitro applications associated with biological fluids, 
other opportunities exist for using such techniques to diagnose solid tumor specimens in 
vitro. The time between diagnosis and treatment could be drastically shortened by use of 
microscopic evaluations of excised tissue samples that provide rapid and reliable results. 
We have shown both qualitatively and quantitatively that nanoshells can be used to 
achieve discernible contrast between cancerous and normal breast cells in 5 minutes. 
These results suggest that gold nanoshells can be designed and optimized to enhance the 
scattering signatures of cancer cells at minimal incubation times necessary for potential 
applications in point-of-care cancer diagnostic imaging. Subsequent studies extend these 
findings from the cellular level to tumor specimen models. 
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CHAPTER 7e 
INVESTIGATE THE USE OF GOLD NANOSHELLS AS CONTRAST 
AGENTS FOR TWO PHOTON MICROSCOPY 
Based on successful experiments demonstrating that gold nanoshells could be 
used to enhance contrast of HER2-overexpressing cancer cells within 5 minutes of 
incubation time, this chapter focuses on a new characteristic of these nanoparticles (two-
photon-induced luminescence) which is subsequently utilized to validate the ability to 
preferentially target HER2-positive cancer cells in a heterogeneous cell population. 
7.1 Introduction 
Accurate cancer diagnosis through its multistage progression IS critical for 
developing effective and selective cancer treatments. In order to provide clinicians with 
functional diagnostic results, knowledge of the molecular signatures of carcinogenesis is 
necessary. Due to their over-expression during the development of cancer, several 
biomarkers have been identified as a biological means of characterizing these signatures. 1 
Although the acquisition of molecular-specific data is typically associated with gene 
arrays and proteomics2, there is an opportunity to use such biomarkers as tools for both in 
vitro and in vivo diagnostic evaluations of tissue specimens, such as during surgery, in 
order to identify malignant cells among heterogeneous tissue. 
e Adapted from: Bickford LR, Sun J, Fu K, Lewinski N, Nammalvar V, Chang J, Drezek RA, "Enhanced 
Multi-Spectral Imaging of Live Breast Cancer Cells Using Immunotargeted Gold Nanoshells and Two-
Photon Excitation Microscopy"; Nanotechnology, 19,315102 (2008). 
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Silica-based gold nanoshells, which are advantageous for several biological 
applications due to their unique optical tunability and potential as multi-modal agents, 
have previously demonstrated enhanced diagnostic imaging potential of carcinogenesis at 
the microscopic scale through the use of extracellular biomarkers3-6• By manipulation of 
the size of their silica cores and gold outer shells, nanoshells can be optically tuned to 
absorb or scatter light from wavelengths ranging from the visible to the near-infrared, 
allowing for both imaging and therapy applications7• Achieving optimal contrast of gold 
nanoshells for biological diagnostics includes a combination of developing nanoshells 
that are tuned to scatter or absorb light in the near-infrared (NIR), where biological 
chromophores absorb minimal light, and the use ofNIR-based imaging systems. 
Although several optical devices have been used to validate applications of gold 
nanoshells as viable contrast agents3-1S, none have focused on evaluating the effectiveness 
of using immunotargeted nanoshells as contrast agents for cell surface biomarkers using 
nonlinear excitation microscopy. Nonlinear optics has been used extensively for 
analyzing fluorescent signals in animal models and tissue samples 16-20. By using a 
femtosecond pulsed laser, two photons can be used simultaneously to excite tissue 
molecules similar to the excitation generated by a single photon, but with twice the 
energy. Only the molecules at the focus of the femtosecond laser will be excited, 
resulting in greater resolution than that achievable with single photon systems, such as 
conventional confocal microscopy. Additionally, unlike conventional confocal 
microscopy, a pinhole is not required to reject out-of-focus light and the inherent 
excitation at only the focal plane means that biological tissue undergoes less 
photodamage2o• Although multiphoton microscopy has frequently been used for 
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energy. Only the molecules at the focus of the femtosecond laser will be excited, 
resulting in greater resolution than that achievable with single photon systems, such as 
conventional confocal microscopy. Additionally, unlike conventional confocal 
microscopy, a pinhole is not required to reject out-of-focus light and the inherent 
excitation at only the focal plane means that biological tissue undergoes less 
photodamage2o• Although multiphoton microscopy has frequently been used for 
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enhancing fluorescent signals16,20, studies have demonstrated that metal particles display 
photoluminescence as a result of excitation by such multiphoton systems21 ,22. This 
photoluminescence is induced by a significant field enhancement that occurs upon multi-
photon excitation of the metallic molecules21 . Thus far in the literature, metallic 
nanoparticles analyzed for two-photon imaging potential have included gold colloid 
spheres23 ,24, gold nanorods2s-29, and gold nanoshells14. A recent publication on the use of 
two photon microscopy for evaluating nanoshell contrast focused on potential dual 
imaging and therapy applications where unlabeled nanoshells were delivered to murine 
tumors through extravasations due to the presence ofleaky vasculature14. However, since 
nanoshell dimensions are fundamentally variable7, it is important to further elucidate and 
confirm the two-photon properties of these highly tunable nanoparticles despite 
differences in size. Furthermore, since cancer undergoes a multistage progression, the 
ability to track molecular signatures through the over-expression of biomarkers is crucial 
in obtaining functional and accurate diagnostic results. Therefore, the goal of our study 
was to demonstrate the nonlinear properties of very different-sized nanoshells and 
validate the proof of concept that immunotargeted nanoshells can be used to enhance 
contrast of malignant human cells in vitro through nonlinear excitation prior to our 
evaluation of this system in excised tissue specimens. Additionally, through the use of 
two-photon excitation and multi-spectral imaging, the simultaneous acquisition of images 
at different emission wavelengths was obtained to ascertain the optimal imaging 
parameters for this system. 
We demonstrate the two-photon luminescence properties of two different sizes of 
gold nanoshells designed with a similar plasmon resonance in the near-infrared. We 
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evaluate the enhanced contrast by comparing HER2-overexpressing breast cancer cells to 
normal breast cells with and without targeted anti-HER2-bioconjugated gold nanoshells 
at five different emission wavelength ranges: 451-483 nm, 483-515 nm, 515-547 nm, 
558-579 nm, and 590-644 nm. By evaluating imaging results under different ranges, we 
explore the broad emission properties of silica-based gold nanoshells under two-photon 
induced luminescence. The anti-HER2 antibody was selected as a model for surface 
tumor targeting due to the association of HER2-overexpression with more aggressive 
breast cancers seen in 15-25% of all breast cancer cases30• Additionally, studies in our 
laboratory have previously demonstrated effectiveness of using immunotargeted 
nanoshells as diagnostic imaging agents for HER2-overexpressing cancer cells3,5-6, 13. We 
show that for immunotargeted nanoshells with a silica core diameter of 254 nm and a 
gold shell thickness of 19 nm imaged with our specific system (set at 10% of maximum 
excitation power), enhanced contrast of HER2-overexpressing breast cancer cells can be 
visualized from 451 nm - 644nm. Under similar conditions, normal breast cells are not 
detectable. Using this information, we also demonstrate the ability to selectively label 
HER2-overexpressing cells with anti-HER2 nanoshells in a heterogeneous cell 
population. 
7.2 Methods and Materials 
7.2.1 Multiphoton Imaging System 
A Zeiss Laser Scanning Microscope (LSM) 510 META multi-photon system was 
used in conjunction with a Coherent Chameleon femtosecond mode locked Ti:Sapphire 
laser to collect two-photon data (Figure 7.1). The wavelength of the polarized output 
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laser beam was tunable between 720-950 nm with pulse width of 140 fs at a repetition 
rate of 90 MHz. A short-pass dichroic mirror (KP700/488, Zeiss) was used to reflect the 
incident NIR excitation light onto the sample through a 20x or 63x objective and to 
collect the two-photon-induced luminescence data. To further eliminate the background 
signal of the excitation light, a wave plate and an IR-blocking filter (BG39, Zeiss) were 
placed in front of the META detector. The Zeiss LSM META system allowed 
simultaneous multi-spectral imaging and recording of up to eight emission channels. The 
maximum output power of the Chameleon femtosecond laser was around 1640 m W for 
excitation at 780 nm. Based on data from the manufacturer, less than 10% of this power 
was incident on the sample. The excitation wavelength of 780 nm was chosen as it was 
within 10 nm of the extinction peak for both nanoshell sizes. 
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Figure 7.1. Schematic of Zeiss LSM 51 0 META Multiphoton System Configuration. 
7.2.2 Nanoshell Fabrication 
Nanoshells were developed as described previously. The two different-sized 
groups of silica particles were measured by scanning electron microscopy (SEM) as 
having diameters of 130 nm and 254 nm. The two finished groups of nanoshells were 
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7.2.2 Nanoshell Fabrication 
Nanoshells were developed as described previously. The two different-sized 
groups of silica particles were n1easured by scanning electron microscopy (SEM) as 
having diameters of 130 nIn and 254 nm. The two finished groups of nanoshells were 
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spectrally analyzed using a Varian Cary 300 UV-vis spectrophotometer (Figure 7.2). The 
final sizes of the nanoshells were determined using SEM imaging (Figure 7.2, insert) and 
confirmed using Mie Theory simulation for multilayer spheres. The smaller nanoshells 
had an average gold shell thickness of 21 nm. The larger nanoshells had an average shell 
thickness of 19 nm. Nanoshells were stored in deionized water at 4°C until further use. 
7.2.3 Nanoshell Surface Modification and Bioconjugation 
For live cell imaging, the larger nanoshells were used and targeted to HER2-
overexpressing cells through conjugations with anti-HER2 antibodies. In order to 
prepare the immunotargeted nanoshells, a heterobifunctionalized polyethylene glycol 
linker (orthopyridyl-disulfide-PEG-N-hydroxysuccinimide ester, OPSS-PEG-NHS, MW 
= 2kD, CreativeBiochem Laboratories) was first conjugated to anti-HER2 antibodies (C-
erbB-2IHER-2Ineu Ab-4, Lab Vision Corporation) as described in Chapter 5. This 
reaction proceeded at a 3:1 molar ratio in sodium bicarbonate (100 mM, pH 8.5) on ice 
overnight. Aliquots of the 'PEGylated' antibodies, at a concentration of 0.4 mg/mL, 
were stored at -80°C until use. Conjugation of the nanoshells to the PEGylated antibodies 
was performed by incubating the nanoshells, at a concentration of 1.6x 109 partic1es/mL, 
with the PEGylated antibodies for one hour under refrigeration (4°C). In order to block 
vacant adsorption sites, the nanoshells were further incubated with a 10 liM polyethylene 
glycol-thiol cocktail (PEG-SH, MW = 5kD, Nektar) for 2 additional hours under 
refrigeration. Unbound antibodies were then removed by centrifugation and the 
immunotargeted nanoshells were then resuspended in deionized water. Prior to 
incubation with cells, the immunotargeted nanoshell solution was further modified by the 
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Figure 7.2. Measured extinction spectra of nanoshells. (a.) N anoshells of average core 
diameter 130 nm and average shell thickness of 21 nm. (b.) Nanoshells of average core 
diameter 254 run and average shell thickness of 19 nm. Inserts depict corresponding 
images from scanning electron microscopy. Scale bars represent 450 nm. 
64 
2 
-.. 
.  
== 
'-' 
= 
.9 
..... 
CJ 
.  
..... 
>< 
.  
 -----~----~----- - -
 0 0 0  0 
ele t  ( ) 
(a.) L---_ _ _ _ ___ _ _ _ _ _ ~_ ' 
2 
'"':' 
.  
 
'-' 
= 
.9 
..... 
CJ 
= :.c 
>< 
.5 
o +--------- -~----~------ ~
0 0  0  900 
avele gt  ( ) 
( .) L.......--____________ --' 
i  . . eas re  e ti cti  s ectra f a s ells. (a.) anoshells f a era e c re 
ia eter  rn a  a era e s ell t ic ess f  rn. ( .) anosheHs f a era e c re 
ia eter  nl  a d a era e s ell t ic ess f  . I serts e ict c rres i  
ilna es fr  sca i  electr  icr sc . cale ars re rese t  . 
 
addition of bovine serum albumin (BSA) and phosphate-buffered saline (PBS) to a final 
concentration of 1 % each. 
7.2.4 Cell Preparation for Visualization of Enhanced Contrast 
SK-BR-3 cells (American Type Culture Collection, ATCC) were grown at 37°C 
in a 5% C02 atmosphere using McCoy's 5A growth medium supplemented with 1% 
antibiotics and 10% fetal bovine serum (FBS). MCF10A cells (ATCC) were also grown 
at 37°C in a 5% CO2 atmosphere using Mammary Epithelial Basal Medium (MEBM) 
supplemented with a BulletKit (Clonetics) and 1% antibiotics. Both cell lines were 
grown in 25-cm2 culture flasks until confluent, rinsed once with 1xPBS, and incubated 
with trypsin-EDTA for 5 minutes at 37°C in a 5% CO2 atmosphere. The trypsin-EDTA 
was then neutralized with the appropriate culture medium and the cells were subsequently 
counted using a hemacytometer. For each cell line, an estimated 6x105 cells were placed 
in each of two 15-mL conical tubes and then centrifuged at 115 x g for 3 minutes. One 
cell pellet was resuspended in the immunotargeted nanoshell solution and the other pellet 
was resuspended in an equal volume of 1xPBS. The cells were then incubated at 37°C in 
a hybridization chamber (VWR International) and rotated under a motor speed of 7 rpm 
for 10 minutes. Post incubation, the cells were centrifuged at 115 x g for 3 minutes, the 
supernatant was removed, and the cells were rinsed once with 1xPBS. Following rinsing, 
cells were resuspended in 10% glucose in 1xPBS in order to maintain cell viability during 
imaging. The cell suspensions were then placed on chambered coverglasses (Fisher 
Scientific) prior to two-photon imaging. 
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7.2.5 Cell Preparation/or Validation o/Nanoshell-Specijic Labeling 
SK-BR-3 cells and MCFI0A cells were grown and cultured as stated above. 
Similarly, the cells were grown to confluence and counted with a hemacytometer. For 
each cell line, an estimated 3xl05 cells were placed in each of two 15-mL conical tubes 
and then centrifuged at 120 x g for 3 minutes. After supernatant was removed, the SK-
BR-3 cells were resuspended in 2 ml of hexidium iodide (Invitrogen, 15 J,lM) and the 
MCFI0A cells were resuspended in an equal volume of 1 x PBS. Samples were then 
incubated at 37°C (under a motor speed of 7 rpm) in the hybridization chamber used 
previously for 15 minutes. The SK-BR-3 samples were then centrifuged at 120 x g for 3 
minutes and resuspended in 1 x PBS. Next, all samples were centrifuged at 120 x g for 3 
minutes. Nanoshells (1.6x l09 particles/mL) were then added to one tube from each cell 
line and then both of these cell populations were combined into one 15-ml conical tube. 
The remaining tubes were resuspended in an equal volume of 1 x PBS (1 ml) and 
similarly combined (control condition). All samples were then incubated at 37°C (under 
a motor speed of 7 rpm) in the hybridization chamber for 5 minutes. Post-incubation, 
both tubes of heterogeneous cells were centrifuged at 15 g for 3 minutes and resuspended 
in 1 ml of a 1:1 SK-BR-3:MCFI0A media solution. An aliquot of cells (~10 J,ll) was 
evaluated for cell viability using Trypan Blue (Sigma Aldrich). 
7.3 Results and Discussion 
By manipulation of the core-to-shell ratio, nanoshells can be designed to strongly 
absorb or scatter light upon near-infrared excitation. In order to validate the two-photon 
characteristics of silica-based gold nanoshells, we designed two different sizes of 
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nanoshells with a similar peak surface plasmon resonance in the near-infrared. After 
fabrication of two different-sized silica cores, their average diameters were confirmed 
through scanning electron microscopy (SEM) as 130 nm and 254 nm. Once the gold 
shell was added, the nanoshells were measured by SEM and their optical properties were 
assessed by UV-Vis spectroscopy. The smaller nanoshells had an average diameter of 
172 nm and a peak surface plasmon resonance at 772 nm; for the larger nanoshells, the 
average diameter was 292 nm, with a peak surface plasmon resonance occurring at 778 
nm (both shown previously in Figure 7.2). Two-photon luminescence properties of the 
gold nanoshells were then observed using a Zeiss LSM 510 META multiphoton system 
with the configuration shown in Figure 7.1. The two-photon properties were verified by 
evaluating the dependence of increasing logarithmic emission intensity on increasing 
logarithmic excitation power. Aliquots of both sizes of bare nanoshells suspended in 
deionized water were well dispersed with sonication and separately placed on chambered 
coverglasses (Fisher Scientific). Data was recorded at an excitation wavelength of 780 
nm which corresponded to the peak plasmon resonance of the nanoshells for both sample 
sizes. The excitation power was varied from 2% to 15% of the maximum laser power 
with a detection spectral band of 494 - 634 nm. By using the image processing software 
inherent in the LSM 510 META system, the average intensities of the nanoshell 
suspensions were obtained. Dependence of luminescence intensity on excitation power at 
780 nm for both smaller- and larger-sized nanoshells was determined (Figure 7.3). The 
slopes of the fitted linear curves are estimated as 2.02 and 2.18 for the smaller and larger 
nanoshells, respectively, in accordance with the characteristic two-photon-induced 
quadratic dependence of emission intensity on excitation power14,16,20. Specifically, 
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Wang et al. demonstrated that the dependence of luminescence intensity on excitation 
power for gold nanorods ranged from 1.97 to 2.17.27 This disparity was attributed to 
possible nanopartic1e melting after increasing the power on the nanorod sample and, 
subsequently, decreasing the power on the same sample. However, in our study, since a 
difference in quadratic dependence exists for two sizes of gold nanoshells treated under 
the same conditions, we believe the nanoshells may actually undergo photophysics which 
are not yet fully elucidated. 
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Figure 7.3. Quadratic dependence of luminescence intensity on excitation power at 780 
nm for two different-sized nanoshells. Nanoshells of core diameter of 130 nm and shell 
thickness of 21 nm are designated as NS 172. Nanoshells of core diameter of 254 nm and 
shell thickness of 19 nm are designated as NS292. Data was recorded with a 20x 
objective. 
In order to demonstrate the enhanced two-photon optical signatures of breast 
cancer cells labeled with immunotargeted nanoshells, the HER2-overexpressing epithelial 
breast cancer cell line, SK-BR-3, was analyzed and compared to the normal breast 
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epithelial cell line, MCF10A, which does not overexpress HER2. For this component of 
the study, the cells were incubated with the larger nanoshells which were conjugated to 
anti-HER2 antibodies. Images were taken of the SK-BR-3 cancer cells under three 
conditions: labeled with nanoshells at 10% of maximum laser power, unlabeled at 10% of 
maximum laser power, and unlabeled at 100% of maximum laser power. An excitation 
wavelength of 780 nm was used for all images and five different emission wavelength 
ranges were analyzed: 451-483 nm, 483-515 nm, 515-547 nm, 558-579 nm, and 590-644 
nm. Additionally, images were taken of the MCF 1 OA normal cells under the same 
labeling and imaging conditions. As shown in Figure 7.4a, bright two-photon 
luminescence signals from nanoshells targeted to cell surface receptors provided clear 
visualization of the SK-BR-3 cancer cells under only 10% of maximum laser power. 
However, under the same power, unlabeled cancer cells were not perceivable (data not 
shown due to lack of detectable signal). By increasing the laser power to 100%, the 
spectral-resolved two-photon-induced auto florescence is evident at emission wavelengths 
ranging from 451 to 547 nm (Figure 7.4b). However, this autoflorescence, which is only 
visible at the maximized power, cannot be discerned beyond an emission wavelength of 
547 nm. With regard to the normal MCF10A cells labeled with immunotargeted 
nanoshells under 10% of maximum laser power, clear visualization of the cells is not 
possible and only a few targeted cell surface receptors can be distinguished (Figure 7.4c). 
Due to the differences in HER2 cell surface receptor expression, which is approximately 
8x105 receptors per SK-BR-3 cancer cell31 and about 1x104 receptors per normal 
MCFIOA ce1l32, the contrast was dramatically increased in the cancer cells due to the 
overexpression of HER2. Similar to the unlabeled SK-BR-3 cancer cells, unlabeled 
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epithelial cell line, FI0A, which does not overexpress HER2. For this co ponent of 
the study, the cells were incubated with the larger nanoshells which were conjugated to 
anti-HER2 antibodies. I ages were taken of the SK-BR-3 cancer cells under three 
conditions: labeled with nanoshells at 10  of maxi u  laser power, unlabeled at 10  of 
maxi u  laser power, and unlabeled at 100  of maximum laser power. An excitation 
wavelength of 780 n  was used for all images and five different e ission wavelength 
ranges were analyzed: 451-483 n , 483-515 nm, 515-547 nm, 558-579 n , and 590-644 
n . Additionally, i ages were taken of the CF 1 OA normal cells under the same 
labeling and i aging conditions. As shown in Figure 7.4a, bright two-photon 
lu inescence signals from nanoshells targeted to cell surface receptors provided clear 
visualization of the SK-BR-3 cancer cells under only 10  of maxi u  laser power. 
However, under the same power, unlabeled cancer cells were not perceivable (data not 
shown due to lack of detectable signal). By increasing the laser power to 100 , the 
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nanoshells under 10  of maxi u  laser power, clear visualization of the cells is not 
possible and only a few targeted cell surface receptors can be distinguished (Figure 7.4c). 
Due to the differences in HER2 cell surface receptor expression, which is approxi ately 
8xl05 receptors per SK-BR-3 cancer ce1l31 and about lxl04 receptors per nor al 
CFIOA ce1l32, the contrast was dramatically increased in the cancer cells due to the 
overexpression of HER2. Si ilar to the unlabeled SK-BR-3 cancer cells, unlabeled 
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MCFIOA cells imaged at 10% of maximum laser power were not detectable (data not 
shown due to lack of detectable signal). Furthermore, images collected at 100% of 
maximum laser power demonstrated that the MCFIOA cells exhibited low levels of two-
photon-induced autoflorescence (Figure 7.4d). Wang et al.27 and Durr et al.29 have 
previously shown two-photon imaging results using gold nanorods. However, the images 
collected were taken over a single emission wavelength range from 400 nm to 
approximately 700 nm. Based on spectral-resolved image acquisition, however, the 
unique widely-spanning luminescence properties of gold nanoshells demonstrate great 
flexibility in selecting the emission wavelengths necessary to minimize the influence of 
background autofluorescence. Photobleaching was also not observed under the two-
photon-induced nanoshelliuminescence. Based on a comparison of live cell brightfield 
images observed before and after laser exposure, morphological changes were not 
detected as a result of the aforementioned laser conditions and, in particular, all cell 
membranes remained visible and intact. 
Exploiting the wide-spanning emission range of the aforementioned (larger) gold 
nanoshells, the ability to preferentially label HER2-overexpressing cells in a 
heterogeneous cell population was evaluated. Hexidium iodide, a nucleic acid stain, 
displays a maximum excitation/emission wavelength at 518/600 nm upon binding to 
DNA. Under two photon excitation (at a laser wavelength of 780 nm), hexidium iodide 
fluoresces strongly from 590 nm to 644 nm. By prelabeling SK-BR-3 cells with 
hexidium iodide prior to incubation with anti-HER2 nanoshells, confirmation of 
preferential nanoshell labeling to these HER2-overexpressing cells over normal cells can 
be easily visualized. Figure 7.5 demonstrates the ability to distinguish MCF 1 OA cells 
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10
10
l lu i
from SK-BR-3 cells in a heterogeneous mixture simply by adjusting the emISSIon 
channels in view using the 510 META detector system. The SK-BR-3 cells, which were 
incubated with hexidium iodide, appear green when the appropriate emission channel for 
hexidium iodide (590 nm - 640 nm) is selected. As shown in Figure 7.5(a.), when the 
emission channel is restricted to the wavelength range spanning 450 nm - 515 nm, only 
cells labeled with nanoshells (which appear red) can be visualized. Once the range is 
expanded to include both the nanoshell- and fluorescence-emission channels, the ability 
to specifically target the SK-BR-3 cells with the HER2-targeted nanoshells becomes 
evident, as only the SK-BR-3 cells are labeled and the MCFI0A cells are only 
perceivable due to the overlay of the phase contrast image (Figure 7.5.(b.), right panel). 
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Figure 7.4. Two-photon images (pseudo color) of live SK-BR-3 cancer cells and MCF10A normal cells in suspension taken at 
different emission wavelengths. (a.) Cancer cells labeled with larger nanoshells at 10% of maximum excitation power. (b.) Unlabeled 
cancer cells at 1000/0 of maximum excitation power. (c.) Normal cells labeled with larger nanoshells at 10% of maximum excitation 
power. (d.) Unlabeled normal cells at 100% of maximum excitation power. Images taken at 63x. Scale bar represents 20 Jlm. 
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Figure 7.5. Merged two-photon and phase contrast images of control and nanoshell-
labeled cell suspensions at 63x. Images take with (a.) nanoshell-emission channel only 
and (b.) combined nanoshell- and fluorescence-emission channels. Nanoshell 
luminescence appears red and hexidium iodide fluorescence appears green. Scale bar 
represents 40 ~m. 
7.4 Conclusions 
Two-photon microscopy is a powerful tool for diagnostic research applications. 
With advancements in gold-based contrast agent development and flexibility in two-
photon excitation wavelength selection readily achieved through tunable laser sources, 
the potential to use multi-photon imaging for assessment of molecular signatures of 
malignancy is substantial. In this study, we demonstrate the first use of immunotargeted 
gold nanoshells as in vitro contrast agents for biomarkers of disease using two-photon 
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microscopy. Additionally, we confirm broad luminescence from gold nanoshells using 
multi-spectral images to visualize the optical contrast provided by anti-HER2-nanoshells 
targeted to live HER2-overexpressing breast cancer cells. Using this broad luminescence 
attribute, we further demonstrate the ability to visualize selective targeting of HER2-
overexpressing cells with HER2-labeled nanoshells in a heterogeneous cell population. 
Our study identifies an additional application of immunotargeted nanoshells and suggests 
their potential future use as multi-functional probes for molecular imaging. 
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CHAPTER8 f 
ASSESS THE RAPID DETECTION OF CANCER CELLS IN HUMAN 
BREAST TISSUE SECTIONS 
The proof of concept that nanoshells can label HER2-overexpressing cells 
preferentially over normal (nonneoplastic) cells within 5 minutes of incubation time has 
set the groundwork for potentially invoking these particles as rapid diagnostic imaging 
agents. In this chapter, we next focus our attention to bringing these findings one step 
closer to clinical practice by evaluating the efficacy of gold nanoshells as rapid imaging 
agents for HER2-overexpressing human tissue sections. 
8.1 Introduction 
The accurate assessment of breast cancer cells at the surgical margins (positive 
margin) is one of the most important factors that can prevent local recurrence in patients 
undergoing breast conservation therapy (BCT)l,2. The presence of positive margin 
predicts for the presence of residual disease still present in the breast near the surgical 
margin. More importantly, it has been associated with significantly increased risk of 
local recurrence after BCT3-5. 
f Adapted from: Bickford LR, Agollah G, Drezek R, Yu TK, "Silica-gold nanoshells as potential 
intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared 
reflectance confocal microscopy"; Breast Cancer Research and Treatment, 120(3),547 (2010). 
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Currently, breast cancer tumor margins are initially examined intraoperatively by 
the surgeon. This gross examination method, if used alone, can result in positive tumor 
margins roughly 50% of the time6. In specialized centers, intraoperative pathology 
evaluation of microscopic tumor margins can be obtained of the resected specimen while 
the patient remains anesthetized. Regions of the specimen that contain suspicious tumor 
margins are processed by either frozen section histology or touch prep cytology 1 , which 
may take as long as 20 minutes. In many community hospitals, this service is not 
available, so the resected specimens are analyzed post-operatively. This process takes 
approximately 24-48 hours to complete due to the series of steps necessary for adequately 
preserving the tissue. 
To enhance visualization of malignancy without the need for lengthy sample 
preparations, optical imaging tools such as reflectance confocal microscopy (RCM)8-11 
and optical coherence tomography12-17 have been studied for both in vivo and ex vivo 
applications. Although results have been promising, authors have noted difficulty in 
distinguishing between normal tissue stroma and cancerous tissue when OCT was used 
alone13 and it has been suggested that incorporating contrast agents targeted to molecular 
markers of disease may incur greater resolution and increased detection of cancer cells 
throughout their multistage progression10,18. Subsequent studies have also evaluated the 
use of targeted metal nanoparticles in tandem with RCM to enhance contrast of cancerous 
cells and tissues19-24. While these results support the ability to improve visualization of 
key cancer signatures with nanoparticle-based imaging, the minimum time utilized to 
achieve a diagnostic conclusion ranged from 30 minutes to 2 hours19-24 for ex vivo 
investigations. 
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In order to realistically improve upon the current standard of tumor margin 
detection in the operating room, the time to achieve a diagnostic result must be kept at a 
minimum. Previously, we demonstrated that targeted gold nanoshells can be used to 
increase contrast of cancer cells that overexpress HER2 receptors within 5 minutes of 
incubation25 • Gold nanoshells, which have a silica core and a thin, gold outer shell, are 
beneficial nanopartic1es for this application because of their tunable optical properties 
and their ability to be conjugated to antibodies. In this study, we translate our previous 
findings to conditions more characteristic of intraoperative tumor margin assessment. 
First, we validate the use of gold nanoshells as effective imaging probes for RCM by 
evaluating contrast enhancement of diverse populations of HER2-overexpressing cells. 
Importantly, we also confirm that these nanoshells, after 5 minutes of incubation time, 
can be used as rapid diagnostic imaging agents for human tissue sections that overexpress 
HER2 receptors. 
8.2 Materials and Methods 
8.2.1 Breast Cancer Cell Lines and Ex Vivo Human Breast Tissues 
Three separate breast cancer cell lines that are known to overexpress different 
levels ofHER2 receptors were analyzed in this study: SK-BR-3, HCC1419, and JIMT-l. 
The normal mammary epithelial cell line, MCF lOA, was also analyzed as a control that 
does not overexpress the HER2 antigen. All cell lines were purchased from the 
American Type Culture Collection with the exception of the JIMT -1 cell line, which was 
purchased from DSMZ (Germany). The SK-BR-3, HCC1419, and JIMT-l cell lines 
were grown with medium (McCoy's 5A, RPMI-1640, and Dulbecco's Modified Essential 
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Medium, respectively) supplemented with 10% fetal bovine serum (FBS) and 1 % 
penicillin-streptomycin. The MCFIOA cells were cultured in Mammary Epithelial Basal 
Medium (MEBM) supplemented with a BulletKit (Clonetics). The cells were maintained 
at 37°C in 5% CO2 atmosphere. 
The human normal and cancerous (HER2+ and HER2-) breast tissue specimens 
were obtained from the Cooperative Human Tissue Network under an Institutional 
Review Board-approved protocol. Cancerous and HER2 status were determined by 
pathologists located at the medical centers where the respective tissues were procured. 
These tissue specimens were initially snap-frozen in liquid nitrogen prior to shipment and 
then immediately stored at -80°C until use. 
8.2.2 Quantification of HER2 Antigen on Cell Surface by Flow Cytometry 
Each cell line was grown to confluency, trypsinized and then counted using a 
hemocytometer. The cells were then incubated with either media alone, PE anti-human 
CD340 (erbB2IHER-2) antibody (BioLegend), or PE mouse IgGl isotype control 
antibody (BioLegend) for 30 minutes on ice in the dark. The cells were then washed, 
resuspended in 500 J.11 of cell staining buffer (BioLegend), and stored on ice until they 
were analyzed at The University of Texas M.D. Anderson Cancer Center (MDACC) flow 
cytometry core for the immunofluorescence intensity of HER2 expression levels. In 
order to determine the mean immunofluorescence intensity for each cell line, we used a 
commercially available kit including PE Anti-Human CD340 (erbB2IHER-2) Antibody, 
cell staining buffer, and a PE Mouse IgG 1 Isotype Control (BioLegend) for background 
signal correction. The immunofluorescence intensity was converted into antigen binding 
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capacity using the Quantum Simply Cellular anti-Mouse IgG kit (Bangs Laboratories, 
Inc.). This kit utilizes four different samples of microbeads with a predetermined number 
of antigen binding sites which correlates with respective immunofluorescence intensity. 
A linear scale is then generated and used for the interpretation of antigen binding sites on 
cell samples of known intensity. 
8.2.3 Nanoshell Fabrication and Surface Modification 
Nanoshells were fabricated as described in Chapter 5 using previous published 
procedures.2s-29 Briefly, silica cores were generated using the Stober method3o and 
surfaces were terminated with amine groups. The final silica particles were measured by 
scanning electron microscopy (SEM) to obtain the average radius of 138 nm. Gold 
colloid of 1-3 nm in diameter was again prepared3! and adsorbed onto the silica cores 
through the amine groups (nanoshell 'seeds'). The gold shell overlay was completed by 
mixing the nanoshell seeds with additional gold solution, potassium carbonate and 
formaldehyde. A UV -vis spectrophotometer (Varian Cary 300) was used to analyze the 
spectrum of the completed nanoshells (Figure 8.1.). Mie Theory was then used to derive 
the absorption, scattering, and extinction coefficients and, subsequently, the 
concentration of nanoshells in solution. As confirmed by SEM, the nanoshells had an 
average radius of 175 nm, a peak surface plasmon resonance at 840 nm and a 
concentration of approximately 2.3 x 109 particles/mL. 
To create molecularly-targeted particles, the nanoshell surfaces were first 
modified by the addition of either specific or non-specific antibodies (anti-HER2/neu or 
anti-IgG, respectively) as previously described. The same custom made 
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heterobifunctionalized polyethylene glycol linker used previously, orthopyridyl-disulfide-
PEG-N-hydroxysuccinimide ester (OPSS-PEG-NHS, MW = 2kD, CreativeBiochem 
Laboratories), was incubated this time with either anti-HER2 antibodies (C-erbB-2/HER-
21neu Ab-4, Lab Vision Corporation) or anti-rabbit-IgG (Sigma Aldrich) at a molar ratio 
of 3: 1 in sodium bicarbonate (100 mM, pH 8.5) overnight on ice and under refrigeration. 
All aliquots were then stored at -80°C. 
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Figure 8.1. Measured spectra ofnanoshells (core radius 138 nm, total radius 175 nm). 
The insert depicts the corresponding image of the nanoshells from scanning electron 
microscopy. Scale bar represents 350 nm. 
In order to perform biological studies, the nanoshells (2.3 x 109 partic1es/mL) were 
incubated with the prepared anti-HER2-linker or anti-IgG-liker solution for 1 hour under 
refrigeration and further stabilized by incubation with a 10 mM polyethylene glycol-thiol 
solution (PEG-SH, MW = 5kD, Nektar) overnight under refrigeration. Nanoshells were 
then centrifuged to remove unbound antibodies and resuspended in water. Prior to 
experimental studies, the nanoshells were brought to room temperature and a solution of 
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bovine serum albumin (BSA) and phosphate-buffered saline (PBS) was added at a final 
concentration of 1 % each. Samples were vortexed briefly before use. 
8.2.4 Imaging Breast Cancer Cell Lines With Nanoshells 
Approximately 6xl05 cells of each cell line (MCFI0A, SK-BR-3, HCC1419, and 
nMT -1) were isolated, washed and incubated with a 2 ml solution of either PBS alone, 
anti-HER2 targeted nanoshells (2x109 particles), or anti-IgG targeted nanoshells (2xl09 
particles). The nanoshell-cell suspensions and controls were then incubated in a 
hybridization chamber (VWR International) at 37°C and 7 rpm for 15 minutes. After 
incubation, the suspensions were centrifuged and rinsed two times with PBS to remove 
unbound nanoshells. The cell pellets were resuspended in 60 JlL of the appropriate cell 
media. This solution was then aliquoted onto a glass slide fitted with a 0.12 mm deep 
spacer (Invitrogen) and then coverslipped. Images of the different cell types were 
obtained with a Lucid VivaS cope 2500 inverted confocal microscope using a 830 nm 
source with a lateral resolution < 2Jlm. The Lucid VivaScope 2500 is a portable, FDA 
approved system used to assess freshly excised tissue in clinics. Images were taken at 
the same distance from the glass surface for each condition and at a power of 1.4 mW. 
The optical intensity of the reflectance of the cells was measured using ImageJ 
processing software. An image of pure black was designated with a value of 0 and that of 
pure white with a value of 255. Average intensity values for each cell line under each 
condition were calculated from 7 independent areas of the respective glass slide used for 
imaging. Images used for this component of the study contained areas where no cells 
were present; therefore, although the intensity of individual cells incubated with HER2-
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targeted nanoshells approach 255 (data not shown), this was not possible for widespread 
images due to the diluted sample allowing certain areas to be void of cells (as seen in 
Figure 8.2). Sample normality was assessed to evaluate the error distribution for all data 
points. A normal probability plot of the residuals verified that the samples followed a 
normal distribution (data not shown). F-tests were also used to determine the equality of 
variance before applying two-tailed paired Student's t-tests to evaluate significance in the 
difference in reflectance intensity of cells between two treatment conditions. 
8.2.5 Imaging Human Breast Tissue Sections With Nanoshells 
Prior to use, samples were thawed briefly in a 37°C water bath and then cut and 
measured to maintain size consistency. Each cut specimen used ranged from 0.21 - 0.26 
grams with dimensions of 5 x 6 mm (length x width) and a thickness of 6 mm. Samples 
were then embedded in frozen section media (BBC Biochemical) and rapidly frozen on 
dry ice. A Leica CM1850 UV cryostat was used to section the tissues at a thickness of20 
Ilm. Four sections were cut per specimen. Normal specimens were sectioned at -35°C 
and cancerous specimens were sectioned at -20°C. The sections were placed on 
superfrost slides (Fisher Scientific) and allowed to air dry for 10 seconds. After drying, a 
20 mm diameter, 1.0 mm deep silicone isolator with adhesive (Invitrogen) was placed 
over each section. The sections were then rinsed twice with PBS prior to incubation with 
blocking reagent (Super Block, ScyTek Laboratories) for 3 minutes at room temperature 
in order to reduce non-specific binding. 
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Figure 8.2. Reflectance confocal microscopy images of (a.) MCF10A, (b.) HCC1419, 
(c.) SK-BR-3, and (d.) JIMT-1 cells incubated with PBS only, nanoshells conjugated to a 
nonspecific biomarker, or nanoshells conjugated to HER2 antibodies. Power at 1.4 m W. 
Scale bar represents 50 Ilm. 
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(c.) S - -3, and (d.) lI T-1 cells incubated ith P S only, nanoshells conjugated to a 
nonspecific bio arker, or nanoshells conjugated to 2 antibodies. Po er at 1.4 . 
Scale bar represents 50 /-l . 
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After blocking, each of three sections received 1.2xl09 particles of the anti-HER2 
conjugated nanoshells and one section received an equal volume (325 Ill) of PBS. 
Samples were then coverslipped and placed on an orbital mixer placed in a 37°C 
incubator for 5 minutes. After incubation, coverslips were removed and samples were 
rinsed four times with PBS to remove unbound nanoshells. Sections were then covered 
with immunomount (Thermo Scientific) and coverslipped for imaging. 
The Lucid VivaScope 2500 inverted reflectance confocal microscope was used 
for image acquisition. F or each slide, images were taken at three different locations, at 
the same distance from the glass surface (~16 11m) and at a power of 0.4 mW to validate 
consistency. After reflectance imaging, coverslips and silicone isolators were removed 
and a new coverslip was placed over the tissue specimens for brightfield imaging. 
Brightfield images were obtained using a Zeiss Axioskop 2 microscope outfitted with a 
color camera (Zeiss AxioCam MRc). All images were taken under the same lighting 
conditions and magnification (20x). 
8.2.6 Immunohistochemistry Staining 
For each frozen specimen, 5 11m sections of tissue were also collected for 
immunohistochemistry (IHC) and hemotoxylin and eosin (H&E) staining. IHC for the 
HER2 antigen was performed using the Histostain Plus (AEC) Broad Spectrum Kit 
(Zymed Laboratories) per manufacturer's instructions. H&E staining was performed 
using the alcoholic Eosin Y solution protocol per manufacturer's instructions (Sigma 
Aldrich). Brightfield images were acquired using the Zeiss Axioskop 2 microscope as 
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described above. All images were taken under the same lighting conditions and 
magnification (20x) to maintain consistency. 
8.3 Results and Discussion 
8.3.1 Enhanced Optical Imaging of Breast Cancer Cell Lines Using Nanoshells 
The goal of this study was to determine if gold nanoshells conjugated to anti-
HER2 antibodies can optically enhance the identification of breast cancer cells that 
overexpress HER2 receptors. Therefore, three breast cancer cell lines (HCC1419, SK-
BR-3, and JlMT-l) that are known to overexpress HER2 and a normal mammary 
epithelial cell line (MCFIOA) were chosen to optimize the binding conditions and 
evaluate specificity of targeted nanoshells. Using flow cytometry, the calculated number 
of HER2-antigen binding sites, along with the 95% confidence interval for each cell line, 
was determined and is shown in Table 8.1. Specifically, the breast cancer cell lines were 
found to have significantly higher (17 to 77 times more) binding sites than the normal 
breast epithelial cells (MCF lOA). 
Table 8.1. Average number ofHER2-antigen binding sites and the respective 95% 
confidence intervals for four different breast cell lines. 
Number of HER2-Antigen 
Bindin Sites Per Cell 
MCFIOA 
SK-BR-3 
HCC1419 
JIMT-l 
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1.7E6 ± 7.7E4 
1.3E6 ± 5.1E4 
3.8E5 ± 1.6E4 
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The capacity of the nanoshells to provide optical contrast of the breast cancer cell 
lines was then assessed using a Lucid VivoScope reflectance confocal microscope, a 
portable reflectance imaging system that is currently used in clinics. Since the nanoshells 
are made with a gold shell and have an optical peak resonance at 840 nm, the cells that 
are bound with the nanoshells clearly reflected more light using reflective confocal 
microscopy than the cells that are not bound to nanoshells. Qualitatively, the reflective 
confocal microscopy images in Figure 8.2 demonstrate that the nanoshells conjugated to 
anti-HER2 antibody bound the most to the three breast cancer cell lines. Most of the cell 
surface could be visualized. The labeling of the cancer cells was very specific against the 
HER2 receptor since the nanoshells conjugated with non-specific IgG resulted in only 
punctate labeling of the same cells. Similarly, only punctate labeling ofMCFlOA normal 
epithelial cells was imaged by the nanoshells conjugated with anti-HER2 antibody. This 
low level of reflectance is likely due the presence of the low level of HER2 receptors 
present on MCFIOA cells, as shown in Table 8.1. 
Quantitatively, the reflectance intensity from each breast cancer cell line with 
HER2 overexpression that was treated with nanoshells conjugated with anti-HER2 
antibody was 5 times higher than the reflectance from normal human breast epithelial 
cells (MCFIOA) treated with the same nanoshells (P<O.OOl, Figure 8.3). For each cell 
line, the binding of nanoshells appeared to be dependent upon the anti-HER2 antibody 
because the reflectance intensity of the cells was 3 to 5 fold higher when the cells were 
treated with nanoshells conjugated to anti-HER2 antibody than to non-specific IgG 
(P<O.OOl). There was no difference in reflectance intensity between any cell type 
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incubated with only PBS (the control condition) (P>0.1) or with IgG-targeted nanoshells 
(P>0.1). 
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Figure 803. Mean quantitative intensity values for samples of MCF10A, HCC1419, SK-
BR-3, and nMT-1 cells incubated with PBS only, nanoshells conjugated to a nonspecific 
biomarker, or nanoshells conjugated to anti-HER2 antibodies. Differences between cell 
types incubated with HER2-targeted nanoshells were not statistically significant (P>O.l, 
n=7). Differences between HER2-overexpressing cell types incubated with HER2-
targeted nanoshells and normal cells incubated with HER2-targeted nanoshells were 
statistically significant (P<0.001, n=7). Error bars indicate standard deviations. 
8.3.2 Enhanced Optical Imaging of Human Breast Cancer Tissue Sections Using 
Nanoshells 
As RCM revealed that HER2-targeted nanoshells could be used to enhance 
contrast in HER2-overexpressing cell lines, we assessed the ability of these nanoparticles 
to visualize breast cancer cells that overexpressed HER2 receptors using ex vivo human 
tissue sections. Specifically, human breast cancer tissues with and without HER2 
receptor overexpresssion (HER2+ and HER2-, respectively) that were resected from 
patients were incubated with HER2-targeted nanoshells or with PBS for 5 minutes. 
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Normal breast tissue was used as a control. As shown in Figure 8.4a, tissue sections 
incubated with PBS showed cells with no perceivable contrast using reflectance confocal 
microscopy. Similarly, qualitative assessment of the imaging of normal and cancerous 
HER2- tissue sections incubated with HER2-targeted nanoshells showed little enhanced 
scattering. However the cancerous HER2+ tissue showed dramatically enhanced contrast 
after only 5 minutes of incubation with HER2-targeted nanoshells (Figure 8.4b.). 
Since tissue without targeted nanoshells shows minimal contrast under reflectance 
confocal microscopy, we also took brightfield images of the same tissue specimens to 
validate the distribution of the nanoshells with respect to the tissue surfaces. As can be 
seen in Figure 8Ac., the nanoshell-targeting seen with brightfield microscopy is 
consistent with the labeling seen in images taken by RCM. The normal tissue section 
shows the least amount of targeting due to the prevalence of adipose tissue, which 
presents as holes within the tissue when cryosectioned. Both cancerous HER2- and 
HER2+ tissues primarily consist of abnormal tissue structures characteristic of 
malignancy. Furthermore, the location and arrangement of the HER2-targeted nanoshells 
corresponds to the results obtained by performing IHC against HER2 (Figure 8.4d.). In 
order to demonstrate the characteristic morphologic variations associated with normal 
and cancerous tissue, H&E stained sections have also been included (Figure 8.4e.). 
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Normal HER2- HER2+ 
-
Figure 8.4. (a.,b.) Reflectance confocal microscopy images of normal, HER2- cancerous, 
and HER2+ cancerous human tissue samples incubated with (a.) PBS or (b.) HER2-
targeted nanoshells for 5 minutes. (c.) Respective images from (b.) taken under 
brightfield microscopy under 20x magnification. (d.) Respective HER2/neu 
immunohistochemistry results taken under brightfield under 20x magnification. (e.) 
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Respective H&E results taken under brightfield microscopy under 20x magnification. 
Power for (a.) and (b.) at 0.4 mW and corresponding scale bar represents 50 J.1m. Scale 
bar for (c.), (d.), and (e.) also represents 50 J.1m. 
A major challenge in intraoperative tumor margin detection is the ability to 
achieve a rapid diagnostic result at the microscopic level directly in the operating room. 
Although tertiary care centers currently address the evaluation of tumor margins during 
surgery, non-specialized institutions do not have access to intraoperative pathology 
assessment. By employing a direct guidance system for the surgeon capable of 
functioning at the point of care, the amount of time patients spend in surgery and the need 
for repeat procedures may be reduced. Additionally, the likelihood of achieving tumor 
resection with negative margins should be improved. Directed re-excision with high 
sensitivity and specificity may also reduce the amount of tissue that would be removed 
and, correspondingly, result in superior cosmesis. In this study, targeted gold nanoshells 
were shown to be an effective contrast agent to improve optical visualization of breast 
cancer cells. The nanoshells specifically bound to breast cancer cells that overexpressed 
HER2 receptors with enhanced intensity of up to 5 fold. 
Earlier studies have evaluated enhanced contrast in cells and tissues by using 
targeted metal nanopartic1es visualized under reflectance imaging19-24 as well as quantum 
dots visualized under fluorescence imaging32• However, these studies examined results 
after long incubation times. In many specialized institutions, intraoperative immediate 
frozen section histology is used to assess surgical tumor margin status. Since the 
incubation times in these studies exceeded the time required to perform frozen section 
histology, the nanoparticles used in those studies are not likely to be clinically 
advantageous. Previously, we showed that silica-based nanoshells could be used to 
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enhance contrast in HER2-overexpressing cells within 5 minutes of incubation time25. 
Here, we show that these targeted nanopartic1es can also be used to enhance contrast in 
human tissue sections with an incubation time of only 5 minutes. In fact, these results 
corresponded to the results obtained with IHC stained against HER2 receptors. 
8.4 Conclusions 
Since nanoshells can be conjugated to a variety of biomarkers, this system could 
potentially be used for several biomarkers associated with breast malignancy. In order to 
translate these findings further into a more immediate diagnostic result in the operating 
room, studies are currently underway to examine the ability to enhance contrast in 
resected human tissue without physical sectioning. Since we propose the assessment of 
tumor margins using the monoclonal antibody HER2 as a molecular marker, we must 
also understand the distribution of HER2 receptors throughout tissue that is considered 
HER2 positive. Specifically, the heterogeneity of this biomarker at the margins of 
tumors from a diverse group of patients who have undergone various neoadjuvant 
therapies must be studied. Our data suggests that the combined use of targeted 
nanoshells and reflective confocal microscopy may provide a more immediate assessment 
of tumor margins based on HER2-expression levels and offer a rapid supplement to 
current diagnostic techniques. 
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CHAPTER9g 
ASSESS THE USE OF GOLD NANOSHELLS AS RAPID IMAGING 
CONTRAST AGENTS FOR INTACT EX VIVO BREAST TISSUE 
SPECIMENS 
Though previous studies have shown that gold nanoshells can rapidly afford 
enhanced contrast of HER2-overexpression in both in vitro cell studies and ex vivo tissue 
sections, the ultimate objective is to discern HER2-overexpressing tissue from 
nonneoplastic tissue without the need for physical sectioning. Therefore, in this chapter, 
we examine the ability to macroscopically and microscopically visualize HER2 
biomarker overexpression in intact ex vivo human breast tissue specimens. 
9.1 Introduction 
Macroscopic visualization of questionable tissue is attractive for enhancing the 
sensitivity and specificity of tumor margin delineation. If the number of suspicious 
regions that require further microscopic processing can be reduced, surgeons and 
pathologists can focus their attention and resources on areas that remain inconclusive. 
Currently, macroscopic evaluation occurs for breast cancer specimens that involve 
microcalcifications or nonpalpable masses and does not occur for palpable breast 
g Adapted from: Bickford LR, Thekkek N, Agollah G, Drezek RA, "Rapid Stereomicroscopic Imaging of 
HER2-0verexpression in Ex Vivo Breast Tissue Using Topically Applied Silica-Based Gold Nanoshells"; 
Breast Cancer Research and Treatment, In Preparation. 
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sensitivity and specificity of tu or argin delineation. If the nu ber of suspicious 
regions that require further icroscopic processing can be reduced, surgeons and 
pathologists can focus their attention and resources on areas that re ain inconclusive. 
Currently, acroscopic evaluation occurs for breast cancer speci ens that involve 
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g Adapted from: Bickford LR, Thekkek N, Agollah G, Drezek RA, "Rapid Stereomicroscopic Imaging of 
HER2-0verexpression in Ex Vivo Breast Tissue Using Topically Applied Silica-Based Gold Nanoshells"; 
Breast Cancer Research and Treatment, In Preparation. 
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masses. I For nonpalpable masses that have been resected, the specimen is first oriented 
with sutures prior to delivery to pathology. The whole specimen is then radiographed 
and then inked by pathologists to further orient the specimen as to in situ location 
(superior, lateral, etc., surfaces). The tissue is next sectioned serially and those sections 
are subsequently radiographed and followed by gross examination. The radiographic 
images are used to determine the extent of the breast disease and the proximity to the 
resected margins. An adequate margin of 1 cm is considered sufficient under standards 
used at MDACC. 1 Although specimen radiography appears to increase the accuracy of 
tumor margin detection, limitations have been noted. For instance, microcalcifications 
are not necessarily associated with malignancy and areas that appear as tumor on 
radiographic images may actually be areas of lymphocytic accumulation due to 
nonneoplastic conditions.2 Additionally, the microscopic extent of the tumor may 
actually be misjudged by radiography.2 In order to increase the sensitivity and specificity 
associated with macroscopic evaluations, the use of contrast agents targeted to specific 
biomarkers associated with disease may present superior opportunities. 
In preceding studies, we confirmed that silica-based gold nanoshells targeted to 
anti-HER2 receptors could be used for the rapid contrast enhancement of both cells3 and 
tissue sections4 which overexpress HER2 biomarkers. To facilitate prompt tumor margin 
detection intraoperatively, the ability to assess tumor margins without the need for 
physical sectioning is highly desirable. Thus, in this study, we advance our previous 
findings by examining the ability to rapidly target HER2 receptors quickly in intact ex 
vivo human breast tissue specimens without sectioning. We first investigate the potential 
depth of penetration of the targeted nanoshells in intact tissue to confirm the 
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predominance of surface targeting and preferential labeling of HER2-positive tissue. 
Then, we demonstrate the proof of concept that anti-HER2 targeted gold nanoshells can 
be used as rapid diagnostic imaging agents for HER2-overexpression in intact breast 
tissue specimens using a standard stereomicroscope and confirm these results through 
reflectance confocal microscopy and immunohistochemistry. 
9.2 Materials and Methods 
9.2.1 Nanoshell Fabrication and Antibody Conjugation 
Nanoshells were fabricated as formerly described.5-7 Silica cores were again made 
using the Stober methodS followed by subsequent termination of the silica surface with 
amine groups. The final particles were measured by direct light scattering (DLS) to have 
an average diameter of276 nm. Next, the aforementioned gold colloid (diameter of ~1-3 
nm) was again fabricated and adsorbed onto the surface of the silica cores via the amine 
groupS.9 After the gold shell layer over the silica cores was completed, the spectrum of 
the final nanoshell solution was visualized using a UV-vis spectrophotometer (Varian 
Cary 300) (Figure 9.1.). 
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Figure 9.1. Measured extinction spectra of nanoshells with an average core diameter of 
276 nm and average shell thickness of 19 nm. Insert depicts corresponding image from 
scanning electron microscopy. Scale bar represents 500 nm. 
In order to determine the concentration of nanoshells in solution, the absorption, 
scattering, and extinction coefficients were determined using Mie Theory. The average 
size of the nanoshells, as validated by Scanning Electron Microscopy (SEM), was a 
diameter of 314 nm with a peak surface plasmon resonance at 840 nm. The concentration 
of the working nanoshell solution was approximately 2.0x109 particles/mL. 
Nanoshells were next targeted to biological HER2-antigens by linking the 
surfaces of the nanoshells to anti-HER2/neu antibodies using previously described 
methods5. Prior to their experimental use, nanoshells (2.0x 109 particles/mL) were 
incubated with the anti-HER2-linker cocktail for 2 hours at 4°C. For the purpose of 
complete nanoparticle stabilization in biological media, the nanoshells were next 
incubated with a 1 mM polyethylene glycol-thiol solution (PEG-SH, MW = 5kD, Nektar) 
for 12-16 hours at 4 °C. Next, unbound antibodies and excess PEG-SH were removed 
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from the nanoshells by centrifugation. Supernatant was removed and, just prior to 
experimental tissue studies, the nanoshells were resuspended in antibody diluent (lHC 
World, pH 7.4) by gentle pipetting to a final volume of 165 Jll. 
9.2.2 Ex Vivo Human Breast Tissue Specimens 
Normal (nonneoplastic) and cancerous (HER2-negative and HER2-positive) 
breast tissue specimens were supplied by the Cooperative Human Tissue Network 
(CHTN) through a protocol approved by the Institutional Review Board (IRS). Tissues 
were previously designated as normal or cancerous by pathologists at the medical centers 
where the tissue samples were obtained. Additionally, HER2/neu status was also 
previously determined by pathologists at the respective medical centers prior to the 
patients undergoing any form of medical treatment. The tissues, which arrived as pre-
frozen in liquid nitrogen, were immediately placed in a -80G C freezer. 
Prior to use, samples were thawed briefly in a 37°C water bath and then cut using 
a disposable cutting board with a 5 mm punch biopsy in order to maintain size 
consistency. At least two punch biopsies were taken from each specimen for control and 
experimental conditions. Each cut specimen used was 5 mm in diameter with an average 
thickness of 1 mm. Tissue samples were subsequently incubated in prewarmed antibody 
diluent (IHC World, pH 7.4) for 1 minute at room temperature with gentle agitation in a 
24-well plate. After pre-rinsing, the samples were incubated in either antibody diluent or 
the aforementioned targeted-nanoshell cocktail (volume = 165 Jll) in polyethylene sample 
vials (Sigma Aldrich). The vials were then placed on a nutator in an incubator set at 37GC 
for 5 minutes. After incubation, the tissue samples were removed from the vials and 
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of 1 x PBS prior to imaging. 
Two Photon Imaging of Human Breast Tissue Specimens 
9.2.3 . 
. b th HER2-negatlve 
. . of intact breast tissue specImens, 0 
For two photon lmagmg 
d HER2 Positive cancerous samples were evaluated for surface labeling of 
cancerous an -
HER2-targeted nanoshells as well as their potential depth of penetration. Samples were 
placed directly on a glass coverslip (Fisher Scientific) and an additional coverslip was 
placed on top of the tissue in order to facilitate moderate tissue compression. For image 
acquisition, a Zeiss laser scanning microscope (LSM) 510 META multi-photon system 
was used in tandem with a Coherent Chameleon femtosecond-pulsed, mode-locked 
Ti:sapphire laser. This system was set to operate at an excitation wavelength of 780 nm 
and a power of 10% of the maximum excitation power. The collected emission 
wavelength range spanned from 451 nm to 697 nm. Images were collected at a 
magnification of 20x and a z-stack (depth) increment of 5 JlIll. In order to calculate the 
percentage of area covered by nanoshells, Image J imaging software was used. An 
intensity threshold of 30 (on a scale of 0 to 255, where 0 represents pure black and 255 
represents pure white) was used to distinguish areas with and without nanoshells. For 
areas that did not contain nanoshells, the associated intensities did not exceed the 
threshold. 
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9.2.4 Widefield Imaging 0/ Human Breast Tissue Specimens 
Normal (nonneoplastic) and HER2-positive cancerous breast tissue specimens 
(from patients who had and had not received previous neoadjuvant chemotherapy) were 
imaged using a Zeiss Discovery.V8 stereomicroscope equipped with a VisiLED MelOOO 
light source. This microscope provides enhanced visualization of specimens in three 
dimensions ranging from Ix to 8x magnification. For macroscopic imaging of breast 
tissue specimens, a thin black pad (taken from a Maestro imaging system) was placed 
beneath a 22x22 glass coverslip (Fisher Scientific) to enable ease of tissue placement and 
to provide a consistent black background among all samples. The specimens (controls 
and respective nanoshell-Iabeled counterparts) were placed alongside each other on top of 
the coverslip. Images were taken at both Ix and 2x magnification under the same 
lighting conditions. 
9.2.5 Reflectance Confocal Microscopy Imaging 0/ Human Breast Tissue Specimens 
Following widefield imaging, the aforementioned samples were prepared for 
microscopic imaging under reflectance confocal microscopy. For this component of the 
study, a Lucid VivaScope 2500 inverted confocal microscope was employed, which uses 
an 830 nm light source and has a lateral resolution of less than 211m. Samples were 
placed directly on glass slides (Fisher Scientific) which were modified by the addition of 
an adhesive l-mm-deep, 20-mm-diameter silicon isolator (Invitrogen). In order to 
compress the tissue slightly and consistently among samples, an adhesive tissue cassette 
(Lucid, Inc.) was placed directly on top of the silicone isolators above the tissue 
specimens. Multiple images were taken at a power of 0.4 m W and at the same distance 
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from the glass surface for tissue samples incubated in either antibody diluent alone or the 
HER2-targeted nanoshells. After reflectance imaging, coverslips and silicone isolators 
were removed and the samples were prepared for histological processing. Additionally, 
reflectance intensity measurements were recorded using Image J processing software as 
described previously.4 
9.2.6 Immunohistochemistry and Histology 
Once images were collected under both stereomicroscopy and RCM imaging 
systems, normal (nonneoplastic) and HER2-positive cancerous samples (with and without 
previous neoadjuvant chemotherapy) were embedded in OCT media (BBC Biochemical) 
and frozen rapidly over dry ice. Sections were then made of all specimens using a Leica 
CM1850 UV cryostat. At least 20 sections were cut from each specimen at a thickness of 
5 !lm. Cancerous specimens were sectioned at -20°C and normal specimens were 
sectioned at -30°C, as suggested by Leica for maintaining optimal tissue morphology. 
The sections were immediately placed on superfrost slides (Fisher Scientific) and allowed 
to air dry overnight. The next day, multiple sections from each specimen of interest were 
prepared for either immunohistochemistry (lHC) or hemotoxylin and eosin (H&E) 
staining. IHC for the HER2-antigen was executed using the Histostain Plus AEC Broad 
Spectrum Kit (Invitrogen) per manufacturer's instructions. H&E staining was also 
performed using the manufacturer's instructions (Sigma Aldrich) for the alcoholic Eosin 
Y solution. For image acquisition, a standard brightfield microscope (Zeiss Axioskop 2 
equipped with a Zeiss Axiocam MRc5 color camera) was used at a magnification of 20x 
under the same lighting conditions. 
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9.3 Results and Discussion 
9.3.1 Distribution and Penetration of Gold Nanoshells In Intact Human Breast 
Tissue 
The goal of this study was to evaluate the distribution of anti-HER2-conjugated 
gold nanoshells through resected intact tissue specimens. For comparison, the nanoshell 
labeling between HER2-positive and HER2-negative tissue samples was evaluated. In 
order to do this, a two photon imaging system was employed. As shown previously, this 
imaging system is capable of enhancing and capturing the luminescence signature of the 
gold nanoshells1o while also creating a stack of images taken in the z-direction 
throughout the depth of the tissue of interest. Figures 9.2 and 9.3 represent the z-stack 
images of HER2-positive and HER2-negative tissues, respectively, incubated with 
HER2-targeted nanoshells. Each sequential increment in the z-direction represents 5 ~m 
into the tissue. Qualitatively, the first image in Figure 9.2 demonstrates that the 
nanoshells preferentially label HER2-receptors on the surface of the tissue. Although the 
tissue was incubated with nanoshells for only 5 minutes, the subsequent z stack images 
illustrate that some targeted nanoshells do penetrate the tissue surface up to 
approximately 20-25 microns, though considerable nanoshell penetration is diminished 
after 10 microns. Based on a comparison with HER2-negative tissue, the nanoshells do 
appear to penetrate the tissue throughout a similar depth, but labeling is reduced due to 
the decrease in HER2 receptor expression. Upon further analysis performed using Image 
J imaging software, which was used to calculate the area of tissue labeled with nanoshells 
at each focal plane, the percentage of nanoshells varied from approximately 42% to 0% 
in HER2-positive tissue from the surface up to 25 microns of penetration depth. For 
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HER2-negative tissue, this range varied from only about 1.5% to 0%. Thus, the 
nanoshelliabeling on the surface of intact ex vivo tissue specimens was approximately 28 
times greater for HER2-positive tissue over HER2-negative tissue. However, at a depth 
beyond 10 microns, this substantial difference in labeling is not qualitatively or 
quantitatively perceivable. 
Figure 9.2. Z-stack two-photon luminescence images of HER2-positive tissue incubated 
with HER2-targeted nanoshells for 5 minutes at 37°C. Each progressive image represents 
an increase in depth penetration of 5 J.lm. Magnification = 20x. Scale bar = 50 J.lm. 
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Figure 9.3. Z-stack two-photon luminescence images of HER2-negative tissue incubated 
with HER2-targeted nanoshells for 5 minutes at 37°C. Each progressive image represents 
an increase in depth penetration of 5 J.lm. Magnification = 20x. Scale bar = 50 J.lm . . 
9.3.2 Enhanced Optical Imaging of Intact Ex Vivo Human Breast Canc(!r Tissue 
Using Gold Nanoshells 
Based on the two photon results demonstrating the superior labeling of HER2-
targeted nanoshells on the surface of intact ex vivo HER2-positive tissue specimens, we 
assessed the potential of using a standard stereomicroscope to .· visualize this enhanced 
contrast. . For this component of the study, human breast tissue specimens that over-
expressed HER2 receptors at the time of patient diagnosis were evaluated. ~nd ·compared 
to normal (nomieoplastic) tissue. Due to the ultimate goal of utilizing gold nanoshells to 
. . 
rapidly label tumor margins intraoperatively, we examined tissue from patients who had 
not undergone previous therapy before surgery as well as tissue from patients who had 
undergone neoadjuvant chemotherapy. All tissue samples were incubated with either 
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antibody diluent buffer or the anti-HER2-targeted nanoshells for 5 minutes at 37°C. As 
shown in Figure 9.4, which represents raw images taken with a stereomicroscope, intact 
tissue specimens incubated with antibody diluent alone showed no markings or features 
characteristic of nanoshells. However, tissue specimens incubated with the anti-HER2-
targeted nanoshells demonstrate numerous particles on the surfaces (and slightly beyond 
the surfaces) of the tissues. Qualitatively, the HER2-positive tissue from the patient who 
did not undergo previous chemotherapy shows the greatest labeling with the targeted 
nanoshells. The HER2-positive tissue from the patient who did undergo neoadjuvant 
chemotherapy does demonstrate enhanced nanoshell labeling, though not to the same 
extent as the patient without previous chemotherapy. In contrast, the nonneoplastic tissue 
shows the least amount of nanoshelliabeling and only a few areas of nanoshells can be 
visually perceived. 
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Figure 9.4. Raw stereomicroscope images of (a.,b.) HER2-overexpressing cancerous and 
(c.) nonneoplastic tissue incubated with either buffer or HER2-targeted nanoshells for 5 
minutes at 37°C. Cancerous tissue taken from a patient (a.) without chemotherapy and 
(b.) following neoadjuvant chemotherapy. Arrows represent nanoshells. Images taken at 
2x. Scale bars = 2.5 mm. 
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While the degree of nanoshell labeling can be visualized without image 
adjustments under a standard stereomicroscope, the superior extent of this labeling can be 
seen more clearly after simple contrast enhancement through imaging software (Image J). 
As seen in Figure 9.5 (a.), the nanoshells are even more discemable against the tissue 
background regardless of inherent tissue constituents. Furthermore, in order to validate 
the enhanced nanoshell labeling seen by widefield imaging, the surfaces of the same 
tissue samples were also imaged using reflectance confocal microscopy (Figure 9.5 (b.». 
Concurring with the stereomicroscopic images, we see dramatic nanoshell surface-
labeling when using targeted nanoshells with previously untreated HER2-positive tissue. 
For the HER2-positive sample which had formerly undergone chemotherapy, we also see 
enhanced nanoshell labeling, though to a lesser degree than the untreated sample as 
suggested by the stereomicroscopy results. The normal, nonneoplastic tissue displays the 
least amount of surface labeling with only minimal nanoshells evident with either 
imaging system. Reflectance intensity measurements (data not shown) demonstrated that 
the HER2-positive tissue samples were ~2.5 to 3 times greater for the treated and 
untreated samples, respectively, than the normal sample. Subsequent histological analysis 
shown in Figure 9.5 (c.) reveals that the distribution of HER2 receptors seen with 
nanoshell-enabled contrast corresponds to that seen with IHC against HER2. The HER2 
expression seen by IHC is greater for the previously untreated HER2-positive tissue 
sample than for the sample which had undergone neoadjuvant chemotherapy. This is 
believed to be due to the effects of chemotherapy and resulting tissue necrosis. However, 
both tissues which were previously identified as overexpressing HER2 during patient 
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Figure 9.5. (a.) Stereomicroscopic images of HER2-overexpressing breast tissue (with 
and witho~t neoadjuvant chemotherapy) and normal breast tissue incubated with HER2-
targeted nanoshells for 5 minutes at 37°C after contrast enhancement. Magnification at 
2x; scale bar = 2.5 mm. Arrows represent nanoshells. (b.) Respective reflectance confocal 
microscopy images of tissue samples from (a.). Power = 0.4 mW and scale bar = 75 ).lm. 
Respective (c.) HER2/neu immunohistochemistry and (d.) H&E results taken under 
brightfield microscopy under 20x magnification. Scale bar = 0.35 mm. 
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diagnosis demonstrate considerably more receptors than the normal, nonneoplastic tissue. 
Additionally, H&E-stained sections of all tissue samples have been included (Figure 9.5 
(d.)) to illustrate the microscopic characteristics and differences associated with 
neoplastic vs. nonneoplastic conditions. 
The macroscopic evaluation of resected tissue is currently the standard of practice 
for certain patients undergoing breast conservation therapy at tertiary centers, such as 
MDACC. As mentioned previously, this occurs primarily for non-palpable breast 
cancers.! Furthermore, this extra level of evaluation is not as common in community-
based hospitals. Here, we demonstrate the ability to use targeted gold nanoshells to 
rapidly improve visualization of a specific biomarker associated with disease aggression 
and progression (HER2) in intact ex vivo human breast tissue. By utilizing gold 
nanoshells designed as rapid diagnostic imaging agents, surgeons and pathologists may 
be able to realize tumor margin status after both macroscopic and microscopic assessment 
without the need to transfer the tissue sample out of the operating room. 
The ability to enhance contrast of malignancy using topically-applied agents has 
previously been demonstrated for oral tissue using fluorescently-Iabeled deoxy-glucose 
and epidermal growth factor (EGF) conjugatesll ,12 as well as cervical tissue using 
fluorescently-Iabeled gold nanoparticles targeted to EGF receptors 13. However, these 
studies employed incubation times ranging from 30-45 minutes, which exceeds the length 
of time currently needed to obtain tumor margin status using frozen section histology. 
Additionally, the aforementioned studies which evaluated malignancy based on EGF 
expression utilized optical clearing agents, which may be necessary for particles which 
target intracellular biomarkers.!4,15 Nevertheless, gold nanoshells targeted to extracellular 
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biomarkers may offer more favorable opportunities for ex vivo intraoperative tumor 
margin detection without the need for lengthy incubation times or the use of optical 
clearing agents. 
9.4 Conclusions 
Recently, we verified that silica-based gold nanoshells could be used to enhance 
contrast of both HER2-overexpressing cells and tissue sections within 5 minutes of 
incubation time.3,4 We take these findings one step further and confirm that these 
particles, when targeted to anti-HER2 receptors, can also be used to distinguish intact 
HER2-overexpressing ex vivo tissue from normal tissue within the same incubation time. 
Moreover, these results are supported by microscopic imaging with a reflectance confocal 
microscope as well immunohistochemistry against HER2. 
In order to translate these findings more readily to the clinic, we are presently 
developing a low cost widefield imaging system that can be used to detect the 
overexpression of HER2 (and other extracellular biomarkers) on account of contrast 
enhancement provided by gold nanoshells. In addition, we plan to collect data from 
diverse patient populations and assess results with fresh tissue samples. Our research 
indicates that ex vivo tissue specimens labeled topically with silica-based gold nanoshells 
can be visualized by both widefield and high resolution imaging systems. By employing 
widefield imaging intraoperatively, clinicians may be better able to distinguish cancerous 
and non-cancerous breast tissue prior to further microscopic analysis and subsequent 
histological processing. 
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CHAPTER 10 
CONCLUSIONS AND FUTURE WORK 
Silica-based gold nanoshells have formerly demonstrated value in a vast array of 
biomedical applications and are expected to play a significant role in the future of 
nanomedicine. Due to their unique design, these nanoparticles can serve as diagnostic or 
therapeutic agents simply by alterations in their core size and gold shell thickness. More 
recently, nanoshells have shown their ability to also act as rapid diagnostic imaging 
agents which may create new venues for their importance in medicine. For instance, by 
implementing photonics-based tools and nanoparticles, the potential of assisting surgeons 
to better distinguish cancer vs. non-cancer directly in the operating room may ultimately 
and effectively reduce the amount of time spent in surgery while providing a means of 
obtaining rapid diagnostic information. 
In this thesis, silica-based gold nanoshells demonstrate their potential to be 
engineered to function as both macroscopic and microscopic tools for the rapid 
identification of HER2-overexpression associated with malignancy in breast cancer. This 
is accomplished through a series of four sequential projects, which translate findings 
from in vitro cell studies to studies of ex vivo tissue sections, and ultimately, to ex vivo 
intact tissue specimens. 
Undoubtedly, the realistic use of gold nanoshells as rapid diagnostic imaging 
agents in a clinical setting will require that certain additional objectives be met. While 
the proof of principle that HER2-targeted gold nanoshells can be used to realize HER2-
overexpression in cell and tissue studies has been demonstrated, it is imperative that a 
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sequence of other experiments be carried out so that adequate adjustments can be made to 
these procedures for clinical translation. 
First, a simplified widefield imaging system should be developed or utilized such 
that the contrast enhancement provided by the gold nanoshells is visible without the need 
for large or costly pieces of equipment. Ideally, this instrument would be easy to use and 
would not occupy much space in the operating suite. Additionally, for those centers 
interested in using reflectance confocal microscopy, a system with a handheld probe, 
rather than the tabletop version employed in this thesis, is recommended. This is due 
largely for maintaining procedural simplicity: a handheld probe would not require 
additional materials, such as glass slides or spacers, and questionable areas would be 
easier to interrogate. 
In addition to optimizing imaging tools, studies should be executed with fresh 
tissue specimens, rather than frozen, which may incur the need for different procedures or 
reagents to acquire rapid labeling. Although 5 minutes was consistently used as the 
minimum incubation time throughout this work, it is possible that an even lower time 
may be effective. Thus, exploring opportunities to reduce this time may prove beneficial. 
While studying the efficacy of rapid labeling with fresh tissue, it is also necessary 
to consider true 'tumor margin' tissue to correlate the results of nanoshelliabeling with 
standard procedures of tumor margin detection. This will necessitate the collaboration 
with a medical center and, specifically, a pathologist who can confirm results. Once the 
rapid labeling procedure has been optimized for fresh, tumor margin specimens, 
appropriate statistics should ensue with corresponding specificity and sensitivity data. 
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Aside from optimization of nanoparticles, equipment, and procedures, the 
distribution of HER2 receptors throughout HER2-overexpressing tissue should be 
understood based on diverse patient populations who have either had no previous 
therapies prior to surgery or who have different neoadjuvant therapies prior to surgery. 
In this way, the use of gold nanoshells may demonstrate widespread efficacy or be 
limited only to specific patient subsets. 
By optimizing nanoshell design and developing superior, cost efficient imaging 
tools, a novel guidance system may be designed for assisting surgeons in distinguishing 
malignancy from benignity. Ultimately, this system could also be used for other 
diagnostic applications, for other anatomical locations, and for other biomarkers 
associated with disease. While rapid diagnostic imaging agents may have many potential 
applications, this research may be implemented in the near future in the area of 
intraoperative tumor margin delineation. By facilitating fast and accurate tumor margin 
results intraoperatively and supplementing current diagnostic methods, the incidence of 
cancer progression and amount of time spent in surgery due to inadequate tissue removal 
is, correspondingly, expected to be reduced. 
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